

Antibiotice **a+**

MANAGEMENT REPORT

65 years
Antibiotice

Half-yearly report according to **IFRS**

Report date: **August 14, 2020**

Name of trading company: **Antibiotice SA**

Head Office: **Iasi, 1 Valea Lupului St.**

Phone number: **0232/209000, Fax 0232/209633**

Fiscal registration code: **RO 1973096**

Order number in the Trade Register: **J22/285/1991**

Regulated market on which the issued securities are traded: **Bucharest Stock Exchange**

Subscribed and paid up capital: **67,133,804 LEI**

Main characteristics of the securities issued by the company: **nominative shares, nominal value: 0.10 LEI**

First semester 2020

CONTENTS

I Context

II **Our company's presentation**

III Shareholding

IV Current activity

- Internationalization of our business and its consolidation in the internal market
 - Consolidating internationally our business
 - Antibiotice in the Romanian pharmaceutical market
 - Evolution of the pharmaceutical market in Romania
 - Antibiotice in the Romanian pharmaceutical market
- Adapting strategically our portfolio
 - Research-Development for the sustainable adaptation and consolidation of our portfolio
 - Renewal of our product portfolio
 - Authorization/re-authorization of our products and their registration in new markets
 - Center of Clinical Studies
 - Complex manufacturing structure compliant with the international quality standards (GMP and FDA)
- Accelerated sustainable development through performing investments and efficient patrimony management
 - Accelerated sustainable development through performing investments
 - Efficient management of our patrimony
- **Adapting our human resources to the company's strategic directions**
 - Efficiency of salary expenses
 - **Non-discriminatory staffing, training of our employees'** skills needed to achieve their objectives and increasing their involvement
 - **Strategies and measures to increase our employees' motivation**
 - Providing a favorable working environment and an organizational culture oriented to innovation and performance
- Integrated quality management
 - Calitate certified quality
 - Labour health and safety
 - Environmental responsibility
 - Antibiotice, a responsible company involved in the sustainable development
 - Prevention and management of emergency situations
 - Solidarity and responsibility

IV Corporate governance

- Governance Code
- Code of Ethics
- General Meeting of Shareholders
- Management Board
- Advisory Committees
- Executive Management

VI Conclusions

I. Context

After an encouraging first quarter, months of declining consumption have followed, in which the company have taken steps to protect its employees and business. Antibiotice has made available to the health system medicines included in the treatment associated to Covid 19 (sterile powder for injection), generic medicines widely used all over the world - carbapenems, penicillins, cephalosporins, which has been ranking Antibiotice as a national and regional leader for over 40 years.

Antibiotice has adapted its oral medicine portfolio si-a adptata portofoliul si pe medicamentatia orala, immediately after the announcement of the crisis of basic medicines by manufacturing Paracetamol and Novocalmin highly sought medicines during this period.

The new reality in the last 2-3 months have determined our company to change its production plans to put its employees' health and safety first, while adapting to the declining market pace.

II. Our company's presentation

Antibiotice SA is the most important Romanian manufacturer of generic medicines, a nationally and internationally reference brand which has been continuing its mission of producing quality, safe and efficient medicines for 65 years.

Antibiotice SA:

- the main manufacturer of anti-infectives in Romania, a leader in the production of injectable beta-lactam antibiotics;
- leader in the production of topicals (ointments, creams, gels) in the Romanian market;
- its exports account for 50% of the turnover;
- ranks first globally in the production of the active substance Nystatin, our product being the USP Reference Standard - an international quality standard;
- has a portfolio comprising over 150 products from 12 therapeutic classes: cardiovasculars, dermatologicals for topical use and inflammatories, digestive tract and genitourinary medicines and food supplements;
- has 8 manufacturing flows for the following pharmaceutical dosage forms: penicillin powders for injection, penicillin capsules, non-beta-lactam capsules,

cephalosporin capsules, tablets, ointments, creams, gels; suppositories, pessaries, active substances obtained through biosynthesis;


- holds internationally recognized certifications and authorizations:
 - authorization for Nystatin and injectable penicillin products granted by the Food and Drug Administration (FDA) , the US drug regulatory body;
 - Certificate of Suitability (COS) with the European Pharmacopoeia for Nystatin;
 - Good Manufacturing Practice (GMP) certificate for all the manufacturing flows, Integrated Management System (quality, environment , occupational health and safety);
 - has a modern Research-Development Center and a Clinical Studies Center;
 - is the first European company prequalified by the World Health Organization (WHO) for the range of essential first-line antituberculosis medicines.

III Shareholding

Antibiotice SA is a trading company in which the majority shareholder is the Ministry of Health with 53.0173% of the subscribed and paid-up capital. Bucharest Stock Exchange (BVB) is the regulated market in which the securities issued by Antibiotice SA are traded in the PREMIUM category.

The main Antibiotice shareholders on 30.06.2020 (*extracted from the Shareholders' Registry*):

- Ministry of Health (*) - 53.0173%,
- S.I.F. Oltenia(*) - 18.9645%
- Broadhurst Investments Limited - 4.1977%
- S.I.F. Transilvania - 3,2632%
- S.I.F. Banat-Crisana S.A - 2.1104%
- A-Invest - 0.6846%
- Private Pension Fund ARIPI/GENERALI S.A.F.P.P. - 0.6782%
- Private Pension Fund Metropolitan Life - 0.4689%
- FDI BT MAXIM Adm. BT ASSET MANAGEMENT SAI S.A. - 0.3947%
- S.C. DEDEMAN S.R.L. - 0,3407%
- Other legal and natural persons - 15.8798%



Ownership breakdown:

- Legal persons - 86.7881%
- Natural persons - 13.2119%

Antibiotice in the capital market

Antibiotice **SA Iasi**, issuer of securities under the ATB symbol, has been listed in the PREMIUM category of the Bucharest Stock Exchange since 1997.

The first transaction was recorded on April 16, 1997, at a reference price of 0.3500 LEI/share. The historical maximum was reached on July 10, 2007, at the price of 2.1700 LEI/share and the historical minimum of 0.0650 LEI/share was recorded on June 8, 2000.

The Antibiotice (ATB) shares are included in the BET-Plus index, (which comprises the Romanian companies listed on the BVB market that meet the minimum selection criteria, except for financial investment companies), BET-XT® (BUCHAREST EXCHANGE TRADING EXTENDED INDEX) - which reflects the evolution of the prices of the 25 most traded companies in the regulated market of BVB, including the financial investment companies (SIFs) and BET-XT-TR (is the total return type of the BET-XT index, which includes the 25 most traded Romanian companies listed on BVB). The BET-XT-TR index reflects both the evolution of the prices of the component companies and the dividends offered by them.

In the first half of 2020, the minimum ATB share price was 0.5100 LEI. The share price has risen to a maximum of 0.5500 LEI/share.

Stock market capitalization of Antibiotice on June 30, 2020 was 359,166 thousand LEI.

In this period 10,404,214 shares were traded, amounting to 43,337 LEI (8,988 EUR, 9,873 \$), with an average price of 0.5123 LEI/share.

Antibiotice shares - ATB / Regular Market

	2016	2017	2018	2019	H I 2020
Number of shares	671,338,040	671,338,040	671,338,040	671,338,040	671,338,040
Stock market capitalization (thousand LEI)*	349,096	361,180	326,942	341,040	359,166
Stock market capitalization (thousand EUR)*	76,875	77,511	70,100	71,370	74,173
Stock market capitalization (thousand \$)*	81,123	92,813	80,259	79,873	83,077
Total traded value (million LEI)	6	12	9	15	0,4
No. of traded shares	12,555,866	21,113,565	17,109,263	30,364,292	855,903
Opening price (LEI/share)	0.5320	0.5200	0.5780	0.4800	0.5400
Maximum price (LEI/share)	0.5420	0.5920	0.5780	0.5260	0.5500
Minimum price (LEI/share)	0.4200	0.5200	0.4550	0.4500	0.5100
Price at the end of the period (LEI/share)	0.5270	0.5380	0.4870	0.5080	0.5350
Average price (LEI/share)	0.5032	0.5585	0.5028	0.4851	0.5294

* Calculation based on the share price in the last trading day of that year

The rights of the holders of financial instruments

The corporate governance framework adopted and applied:

- protects the shareholders' rights;
- ensures the fair treatment of all shareholders;
- recognizes the role of third parties with interests in the company;
- guarantees the provision of information and its transparency;
- assures the responsibility of the Management Board towards the company and the shareholders.

On the company's website at www.antibiotice.ro/investors/informationforshareholders, there is a section dedicated to our shareholders, where they can access and download documents related to the General Meetings of Shareholders: procedures regarding the access and participation in the meetings, the notice to attend, additions to the agenda, informative materials, special representation proxies, correspondence voting forms, decision drafts, decisions, voting results, etc..

Antibiotice makes available to all interested the periodical and annual financial statements prepared according to the legislation in force. The company also complies with all disclosure requirements under the laws of commercial companies and capital market.

Our company has a department specialized in the relations with the existing and potential investors, called Investor Relations, which has as main roles to implement and monitor the corporate governance standards within our company, to inform the shareholders and investors in accordance with the legal provisions, to proactively communicate with our investors focused on their information needs.

The persons appointed to keep in touch with the investors deal with the shareholders' requests with maximum efficiency and facilitate the dialogue with **our company's** management. Our company creates and develops an appropriate policy to promote an effective communication with our investors and shareholders.

Antibiotice SA - member of the Romanian Investor Relations Association (A.R.I.R.)

Being always oriented towards development and increasing the transparency towards the shareholders, in completing the strategy of improving the quality of the relationship with the investors and out of the desire to create value for the shareholders, on July 31, 2019, Antibiotice joined the Romanian Investor Relations Association (A.R.I.R.), a vibrant community in the Romanian capital market.

The Romanian Investor Relations Association (A.R.I.R.) is a non-governmental and non-profit organization established in order to provide current and potential issuers with a platform for the development of professionals in the field of investor relations (IR) and contribute to the implementation of best practices in investor communication and governance corporate.

For its Investor Relations activity and for the degree of transparency, accuracy and completeness of the information and accessibility of its website, in 2020 Antibiotice got the 10 score granted by the Romanian Investor Relations Association that evaluated 78 issuers in the Romanian capital market.

Antibiotice achieved this performance by approaching new and efficient communication tools. This way, the investors, analysts, brokers, journalists have the opportunity to learn about the Antibiotice business.

IV Current activity

Our company's activity carried out in the first semester of 2020 was influenced by the exceptional circumstances generated by the SARS-COV 2 coronavirus pandemic which led, among other things, to the establishment of a state of emergency in Romania.

Aiming at achieving the indicators included in the Management Plan, the activity was oriented towards the strategic development directions:

1. Internationalization of our business and its consolidation in the internal market
2. Adapting strategically our portfolio
3. Accelerated sustainable development through performing investments and efficient patrimony management
4. **Adapting our human resources to the company's strategic directions**
5. Integrated Quality Management

Due to legal restrictions, establishment of the state of emergency followed by the establishment of the state of alert, hospital market limited its activity in terms of the number of hospitalizations and thus medicine consumption was reduced, and the retail market was influenced by the limited access of consumers to medicines, leading this way to a reduced demand for some of our company's medicines.

The main financial indicators of the reporting period are as follows:

No.	Indicators	Currency	30.06.2019	30.06.2020	06.2020/ 06.2019
1	Sales income	thsd LEI	172.391	146.378	0,85
2	Gross profit	thsd LEI	24.923	19.351	0,78
3	Arrears	thsd LEI	0	0	1,00
4	Total expenses related to 1000 LEI total income	LEI	879	894	0,98

1. Internationalization of our business and its consolidation in the internal market

Consolidating internationally our business

Against the background of the global crisis of the spread of the SARS-CoV 2 virus, the international trade activity for the medicines for human use has been severely affected. Export restriction measures imposed by the legislation specific to the state of emergency and alert, additional documentation required by the Ministry of Health for the approval of export operations, disruption of the transport of goods, limitation or cessation of production activities for the active substances originated from China, Italy, France, India impacted both the production activity and the international sales, especially in March-April.

Antibiotice SA identified solutions for the continuation of exports, through the relationship with the national authorities and with the external partners.

In this context, our company adapted its business internationally with an anti-infective portfolio associated with the Covid-19 treatment, succeeding to secure its sales in international ATB territories, including the export of Nystatin (active substance).

In the first 6 months of 2020, the export value of medicines and active substance was 73.8 million LEI, a relatively similar value compared to that recorded in the similar period of 2019 (72,7 million LEI), which determined the balancing of the turnover.

Maintaining the leading position in the world market for the active substance Nystatin

In the H1 2020, our export of Nystatin recorded about 40 million LEI, slightly over the value recorded last year, our company maintaining its first position worldwide in production of this active substance.

A 6% increase in average in the consumption of Nystatin was recorded in the markets from North America, Europe, Australia, Asia and Africa. This increase created healthy premises for long-term business consolidation, in the context in which Antibiotice intends to increase the production of Nystatin by streamlining the manufacturing process.

In the states of the Middle East (Siria, Irak, Iran), Antibiotice SA adopted in the first semester of 2020 a prudent commercial and financial policy, meant to stop the downward trend of the price, but also to secure the collection of receivables.

Maintaining the sales in the territories where the company has its own representative offices

In the existing pandemic context, it was necessary to recalibrate the international trade strategy, aiming to guarantee production and stocks for the Romanian hospitals and international territories where our company opened its own representative offices: Republic of Moldova, Serbia, Vietnam, Ukraine. In this approach, the sales in the international ATB territories remained at the same level as in 2019, recording the value of 10 million USD.

The pandemic imposed measures to restrict circulation, distance, quarantine or isolation, and the access of the population to pharmacies was thus mainly aimed at chronic medication and that associated with Covid-19 treatment. The structure of consumption showed a 5% increase of the export value for cardiovascular and anti-pyretic medicines in the Republic of Moldova, Vietnam, Serbia.

Supporting the international health systems

Through the local distributors, Antibiotice honored requests from international health systems, supporting them with anti-infective drugs included in the Covid-19 treatment. Our company won tenders in the USA, Great Britain, Hungary, for about 2.5 million vials and managed properly the doubled demand of sterile penicillins in the Scandinavian countries (Denmark, Norway), made exports urgently requested by the governments from Lithuania, Latvia and the Netherlands.

Antibiotice mobilized also its resources and responded positively to the request of developing countries, Irak and Yemen, to help them with medicines for treatment in hospitals.

Antibiotice in the Romanian market

Evolution of the Romanian pharmaceutical market^[1]

¹according to CEGEDIM Sell Out Romania June 2020


In the first 6 months of 2020, the value of our medicinal products released to patients in Romania amounted to 8.7 billion LEI (distribution price), down by 3.9% compared to the value recorded in 2019.

March represented a peak in the sales but, in the following months, there was a major contraction in consumption on all the sales channels, due to the restrictions applied

with the entry into force of the state of emergency and subsequently the state of alert. The result was a sharp decrease in the number of consumers in open circuit pharmacies, but also in the number of hospitalizations (being registered only in hospitals with Covid regime).

Monthly evolution of the total market 2020 vs 2019 - 6 months

Quantity - boxes Distribution price value



The Romanian pharmaceutical market is dominated by prescription medicines (RX). These represent 74.7% of the total value sales and 62.7% of total drug consumption (reported in boxes).

Prescription medicines recorded in the analyzed period an 8% decrease in value, from 7.07 billion LEI in 2019 to 6.5 billion LEI in 2020.

As regards the number of boxes released from pharmacies, a 4.2% drop was recorded, from 203.9 million boxes to 195.3 million boxes in the first half of 2020.

In the analyzed period, over-the-counter products recorded an increase in value by 10.5%, from 2 billion LEI in 2019 to 2.21 billion LEI in 2020. The number of boxes released from pharmacies rose by 5.4%, from 110 million boxes to 116 million boxes in the first half of 2020.

Compared to 2019, from quantitative viewpoint, the most affected segment in the first 6 months was the hospital segment, which recorded a 9.1% decrease from 14.48 million boxes sold in H1 2019, to 13.16 million boxes.

The "National chains" segment reduced its sales value by 14.2% from 3.56 billion LEI in H1 2019 to 3.05 billion LEI in the similar period of 2020.

Independent and mini-chain pharmacies had a relatively constant quantitative and value evolution, recording value sales of 4.48 billion LEI and about 185 billion boxes from quantitative viewpoint in H1 2020.

Evolution of the relevant pharmaceutical market for Antibiotice SA


The relevant market of the products from the Antibiotice portfolio had a slight 2.2% increase, from 1.053 billion LEI to 1.077 billion LEI. Quantitative consumption decreased by 3%, a number of 65.6 million boxes being released from pharmacies.

Prescription medicines (RX) represent about 52.2% of total value sales and 61.7% of total medicine consumption (reported as boxes). In the analyzed period, they recorded a 2% value decrease, from 572 million LEI in H1 2019 to 562 million LEI, in the same period of 2020.

Over-the-counter products (OTCs) recorded a value increase of 7%, from 482 million LEI in the H1 2019 to 515 million LEI in the H1 2020.

The first therapeutic classes in the Romanian pharmaceutical market, taking into account their share in the value sales are: Digestive tract, Oncology, Antiinfectives for systemic use, Cardiovascular system, Central Nervous System. These represent 70% of total sales in the pharmaceutical market.

Value evolution in the top 10 therapeutic classes



Antibiotice in the Romanian pharmaceutical market

Antibiotice SA followed the market trend in the first semester of 2020, the gross value of Antibiotice sales to patients amounted to 152.3 million LEI, dropping by 8.8%, compared to H 1 2019, however maintaining its strengths :


- Ranks first in the relevant market, with a 14% value market share;
- Leader in terms of quantity for the following dosage forms: ointments (23.6%), suppositories and pessaries (40.9%) and injectable powders (67.5%);

- Leader in the segment of generics and OTCs sold in hospitals, with a 15.8% market share;
- Ranks 8th in the segment of generics and OTCs (3.9% market share);
- Ranks 20th in the total pharmaceutical market (1.75% market share)

Two thirds of sales to patients are from the Anti-Infectives, Cardiovascular and Dermatology portfolios.

Evolution in terms of value of the first 5 therapeutic classes - **ANTIBIOTICE**

Central Nervous System, Digestive Tract, Dermatological Preparations, Cardiovascular System, Anti-Infectives,



In terms of value, the Hospital segment recorded an increase of about 6.4%, from 38 million LEI in H1 2019 to 40.4 million LEI in the same period of 2020 (the data concern exclusively the sales of the products included in the 2020 plan). This growth is higher than the average growth rate of the relevant market (+5.8%). The number of sold units released from hospitals remained relatively constant at 13 million units.

Retail market registered a decrease of value of about 9.7% in the first semester of 2020 compared to the same period of 2019 (the data concern exclusively the sales of the products included in the 2020 plan). If, in the first quarter the value sales were constant compared to the previous year, in the second quarter, due to the general context, they recorded a contraction of about 21%.

The most affected segment was that of pharmacy chains that fell with 12.7% compared to the previous year, but this decrease was lower than that recorded by the pharmaceutical market for the mentioned segment (-14.2%).

The value sales recorded in the independent and mini-chain pharmacies dropped by 7.8% in the analyzed period of 2020 compared to the same period of 2019, while the number of boxes released from pharmacies decreased by 3.4%.

The products that recorded significant increases compared to the previous year are: Moldamin®, Meropenem for injection, the range, Amoxiplus® inj, Bisotens® range, Nolet®, Cicloserina®, Penicilina Gk 1 mil.

Standing in solidarity with the Romanian health system also in the context of the SARS-COV coronavirus pandemic, our company's representatives kept in constant contact with the distributors, in order not to have syncope in the supply of medicines and create stocks to honor the orders as soon as possible. At the same time, they constantly contacted the hospital pharmacies to identify the need for medicines and quickly honors the orders launched by hospitals.

Also, to meet the specific needs of this period of the health system, Antibiotice SA adapted its manufacturing structure and produced Paracetamol tb 500mg and Novocalmin tb 500mg, molecules for the COVID-19 treatment.

As a gesture of solidarity towards the medical system, Antibiotice offered both financial aid and donations in medicines for ten hospitals in Romania.

Strategies for promoting the products from the Antibiotice portfolio

In the Q1 2020, the Antibiotice portfolio was mainly promoted through medical visits to various medical specialists and pharmacists, as well as through scientific events organized in hospitals, outpatient clinics and pharmacies. Promotional actions aimed to increase the good reputation of our company brand as well as the product brands from the following classes: anti-infectives for systemic use, dermatological preparations, medicines for genito-urinary system, musculoskeletal system and the Nutriensa® range of food supplements.

In the second quarter, as a result of the declaration of the state of emergency and subsequently of the state of alert, we adapted the promotion strategy to the new market conditions. Thus, the medical representatives conducted their promotion activity using the telephone, e-visits via the Internet or by combining direct visits with promotion by telephone calls.

In the pandemic context, the recommendation and consumption of drugs for chronic non-communicable diseases has seen an upward trend. Thus, starting with June, in addition to the products promoted in the first months of the year, the medical promotion for the products from the cardiovascular portfolio was resumed to the cardiologists and family doctors.

Also as a measure of adaptation to the new conditions, the promotion of the **Antibiotice's** products was carried out in webinars for doctors and pharmacists through online promotion actions, promotion campaigns on blogs and Social Media (Facebook, Instagram) with posts, contests and advertorials.

From the wide range of products manufactured by Antibiotice, our representatives promoted products belonging to the following portfolios: Hospital & Partners, portfolio for dermatology, portfolio for the prevention but also for the treatment of various **diseases brought together under the "Quality of Life" concept.**

Hospital&Partners is the portfolio for hospitals, the promotion focusing on the development of good practices in the use of antibiotics, supported by the campaign "Antibiotics of the Third Millennium", with a package of messages around the notion of "Judicious / responsible consumption of antibiotics".

Colistina® Atb, AmpiPlus®, Amoxiplus® are the products promoted through direct visits to the customer group hospital.

Moldamin® (benzatyn benzilpenicilina) is the product that brought the novelty among the promoted products, being reintroduced into production at the end of 2019. In this period, **the program entitled "Test! Evaluate! Treat!",** a multidisciplinary public health education program was implemented. It integrates the promotion of the benefits of product reformulation and encourages health professionals, in the context of current infectious pathology, to correctly evaluate, test and treat the patients.

"Quality of Life" is the concept defined in medicine as being the physical, mental and social well-being as well as the ability of individuals to perform their usual tasks. Assessing the personal health by referring to an ideal model is a criterion that determines the quality of life.

The therapeutic solutions brought together under the **"Quality of Life" concept** for the treatment of various diseases are from the following areas: cardiovascular, genitourinary, musculoskeletal, dermatology, digestive tract.

The concept also brings together OTC products, as well as complementary alternatives designed to maintain the body's homeostasis such as food supplements - grouped under the Nutriensa® brand.

"Women's Health" - represents the concept through which Antibiotice aims to consolidate the identity of its portfolio intended for preventing and treating of diseases in obstetrics and gynecology through products from the ranges Zifex pessaries, Nystatin pessaries.

Maintaining the leading status on the topical products segment imposed the need to reposition the brands grouped under the communication concept **"We are where we need to be - Antibiotice - leader in the production of topicals"**. The current context determines us to consolidate and create powerful brands, which is why the action plans included the brands: Cutaden® range, Tinero® gel, Nidoflor® cream.

Antibiotice can effectively develop both domestically and internationally by ensuring a sustainable portfolio by investments for developing in-house new products in compliance with the current therapeutic trends.

Our company's promotion strategy in the current pandemic context involves an adaptation to the use of multiple information channels, especially online, the selection of platforms that facilitate the transmission of synthesized information to health professionals, as well as possible direct visits.

2. Strategic adaptation of our portfolio

- Research-Development for adapting and durably consolidating our company portfolio

The main objective of the Research-Development Unit is to develop new medicines (topicals, tablets, capsules, sterile products and other new pharmaceutical dosage **forms) in line with the company's development** strategic directions until 2025. The products under research will complete the following classes of the Antibiotice portfolio: anti-infectives (sterile oral and injectable powders), dermatological, cardiovascular, non-steroidal anti-inflammatory products, medicines for the digestive system and for women's health.

Of the products under research in 2020, number of 14 projects went through different stages, as follows:

- three projects for the Sterile Products & Nystatin Division;
- five projects for the Topical Products Division;
- six new projects, of which one food supplement for the Oral Solid Dosage Forms Division.

To these research projects actions are added to support the internationalization process of the current portfolio for 16 products (8 solid orals, 4 products for injection and 4 topicals)

In March 2020, Food and Drug Administration approved the Active Substance Master File (ASMF) for the active substance Nystatin. This document certifies the quality of Nystatin and documentation prepared in accordance with the requirements of the certification bodies, the active substance benefiting from a complete characterization from a structural and analytical point of view.

Authorized surface disinfectants, hand sanitizer in the process of authorization

In the context of the increased need for protective materials, Antibiotice started researching and testing disinfectants that can be manufactured on its own manufacturing flows.

These products will be used both to protect our employees and to support the current needs of the Romanian health system.

The research, production and quality teams worked on two types of products: hand sanitizer gels and surface sanitizers. After testing, they selected a hand sanitizer gel formula and two surface disinfectant formulas.

Antibiotice currently produces two surface disinfectant solutions in 1 liter and 5 liter bottles according to the marketing authorization issued by the Cantacuzino Institute, while the formula proposed by our research team for the hand sanitizer gel is ready to be sent for analysis to an external laboratory, in order to be further accredited and introduced in the company's portfolio in the future.

Resumption of production of Paracetamol and Novocalmin® to support the Romanian medical system

Being a pharmaceutical manufacturer that has been supporting the Romanian medical system for 65 years, Antibiotice decided, in the context of the outbreak of the SARS-CoV-2 coronavirus pandemic, to resume the production of Paracetamol tablets and Novocalmin® (metamizole sodium). Antibiotice has the necessary resources such as marketing authorizations (MAs), raw materials, manufacturing know-how and production facilities in order to be able to produce and deliver in the market a whole range of medicines, including those for the symptomatic treatment of COVID19.

Both Paracetamol and Metamizole sodium (prescription medicine) have been included in most of the national treatment guidelines in the EU as a first option when initiating treatment for fever or pain caused by SARS-CoV-2 infection.

➤ Renewal of the product portfolio

In identifying the new products, the analysis of the global pharma market trends was taken into account, with a focus on the main sales markets of the company (ATB territories), identification of the main pathologies for which an increasing epidemiological trend is expected in the next 10 years, as well as the analysis of the portfolios of the main competitors in the market in this product segment, in accordance with the structure by therapeutic classes of the current portfolio.

The development of the topicals portfolio focused on the introduction of products belonging to the following therapeutic classes, intended mainly to improve the quality of life:

- range of products for diseases of the venous system;
- range of non-steroidal anti-inflammatory medicines;
- range of medicines and adjuvants for maintaining the women's health;
- dermatologicals.

The development of the oral and sterile solid dosage forms focused on the introduction in research of medicines for cardiovascular diseases and on the analysis of the list of essential drugs of the World Health Organization.

- Authorization / reauthorization of products and registration in new markets

In H1 2020, our company submitted:

- files for authorization in:
 - EU for 11 products, 5 injectable products and 6 oral solid products;
 - Ukraine for 7 products, 4 injectable products and 3 oral solid products;
 - Vietnam for a topical product;
 - Republic of Moldova for 7 products, 2 injectable products, 4 oral solid products and 1 topical product.
- files for re-authorization in:
 - Romania for 4 oral solid products, 2 topical products and updating medical information, SPC and Leaflet for 16 products;
 - Serbia for one injectable product;
 - Republic of Moldova for one injectable product, one oral solid product and 2 topical products;
 - Georgia for one injectable product.

- Center for Clinical Studies

The activity of the Center for Clinical Studies (CSC) consists in conducting bioequivalence studies, as well as clinical studies established in the annual plans, performing instrumental tests, through specific laboratory techniques for current manufacturing, supporting the research plan by performing specific determinations, development and validation of analytical methods, support of the activity of product registration by offering scientific support in order to clarify some issues raised by partners / authorities, as well as preparation and management of specific documentation in accordance with specific legislative rigors.

- Complex manufacturing structure adapted to international quality standards (GMP and FDA)

In the context of increasing competitiveness and the need to make the activity of the manufacturing plants profitable, we made the decision to reunite the five manufacturing plants on the Antibiotice site in three product divisions, as follows:

1. Solid Oral Dosage Form Division, which integrates the activities of the Capsule Plant and Tablet Plant;
2. Topical Division, integrating the Ointment & Suppository Plant;
3. Sterile Products and Nystatin, which integrates the activities of the Parenteral Plant and Biosynthesis Plant.

The divisions are managed independently in terms of production activities, investments in technology, product portfolio and customers, so as to become autonomous profit

centers, which adapt their manufacturing, product portfolio to the needs and characteristics of the markets where their products are sold.


The H1 2020 production materialized in 224 million pharmaceutical units in the form of tablets, capsules, parenterals, topicals (ointments, creams, gels), suppositories, pessaries. The active substance Nystatin was produced in a quantity comparable to that made in the first semester of 2019.

The total value of the H1 2020 production was 191.6 million LEI, on the 8 manufacturing flows, as follows:

VALUE DISTRIBUTION OF PRODUCTION MADE IN H 1 2020

(% OF THE TOTAL VALUE OF THE PRODUCTION MADE)

Nystatin: 14.2%, Capsules: 19.3%, Parenterals: 22.2%, Tablets: 13.1%, Ointments: 17.3% Suppositories & pessaries: 13.9



3. Accelerated sustainable development through efficient investments and efficient asset management

➤ Accelerated sustainable development through efficient investments

In the H1 2020, our company completed investment objectives amounting to 25,97 million LEI out of the total amount of 78.91 million LEI approved for the whole year 2020 through the investment plan (according to the contracts concluded with the partner companies and with the agreed work schedules).

According to the annual program, the structure of investments in the first half of 2020 was as follows:

Research & Development investments

In the first six months of the year, our company invested in research-development 4.23 million LEI (out of the total amount of 11.53 million LEI, planned for 2020). The

investments were made for equipment and software for supporting and improving the research activities, in order to obtain new quality, safe and efficient products, highly competitive in the market.

Investments in new manufacturing sites

The planned investment for the continuation of the works at the new manufacturing plant for ointments and suppositories has the value of 19.64 million LEI. An amount of 10.92 million LEI were used in the first semester. The works for performing the clean rooms and the related installations continued, correlated with the installation of the equipment and technological installations for the production and transport of the utilities. The works were stopped on March 15, 2020 due to the traffic restrictions imposed by the coronavirus pandemic. The works were resumed starting with the month of June. The degree of achievement of this important investment objective is 91%.

Investments for modernizing the existent manufacturing sites

In order to refurbish the 8 manufacturing flows, our company invested 0.20 million LEI in the first semester of 2020 for purchasing equipment, installations and laboratory equipment (out of the total of 3.20 million LEI, allocated for 2020).

Investments in product quality control, environmental protection, occupational safety and health

Increasing the accuracy of laboratory analysis methods and reviewing monographs in pharmacopoeias have required investments in state-of-the-art equipment to maintain the quality standards of manufactured products and comply with legal requirements to protect the environment and employees. The amount invested in the H1 2020 was 1.51 million LEI (of the annual total of 3.33 million LEI).

Investments for rehabilitating the industrial site

In the first three months of the current year, Antibiotice invested 4.12 million LEI (of the total annual sum of 35.38 million LEI) in the rehabilitation of auxiliary buildings and constructions, transport and storage infrastructure and logistics, maintenance infrastructure, production and distribution of utilities, IT infrastructure, as well as for the rehabilitation of land released after demolition and decommissioning.

Investments in social responsibility projects

In the H1 2020, Antibiotice invested 4.99 million LEI (of the total amount of 5.83 million LEI for 2020) in projects for its employees: **“Friendly brand” which consisted** in arranging the common areas (locker rooms, social groups, dining rooms, training rooms) **and “We live healthy in a healthy company” which included:** modernization of the Penicilina sports hall and the project **for the community called “Friendship Park”** (arrangement of a park in the area with forest shelter-belt in front of our company, adjacent to the DN28 national road).

Efficient patrimony management

Comprehensive income statement

One of the company's strategic objectives is developing its business internationally. However, in the H1, 2020, the SARS-VOC-2 virus pandemic caused syncope in its activity.

Domestically, due to restrictions imposed by the authorities to prevent the spread of SARS-VOC-2 virus infection, as well as the targeting of medical services to patients affected by this virus, drug use in hospitals and pharmacies decreased. Antibiotics especially focused in the international market. Thus, from the sales revenue amounting to 146,377,930 LEI, 50% represents sales in the foreign market.

The value of other operating income was higher by 19% compared to the value recorded on 30.06.2019.

The research and development activity is a continuous concern for the company, pursuing the development of valuable molecules for patients' health, as well as supporting the objective of internationalizing the business, by permanently adapting the formulas of medicine from our portfolio to the registration requirements in other countries. Thus, compared to the value recorded on 30.06.2019, the value of income from the activity performed by the entity and capitalized is higher by 28%.

Interest recorded in the H1 2020 on contracted bank loans, higher than financial income (represented by favorable exchange rate differences on the settlement of receivables and payables) led to a value of net financial income of -3.017.557 LEI.

Indicators	Financial year		30.06.2020/ 30.06.2019
	30.06.2019	30.06.2020	
0	1	2	3=2/1
Sales income	172,391,095	146,377,930	0.85
Other operating revenues	18,686,567	22,243,720	1.19
Income related to the cost of product stocks	26,243,033	26,727,927	1.02
Income generated by the entity and capitalized	2,568,485	3,295,615	1.28
Expenditure on raw materials and consumables	78,018,365	66,398,931	0.85
Staff costs	46,888,473	50,146,132	1.07
Amortization and depreciation expenses	10,329,494	10,959,958	1.06
Other operating expenses	57,508,252	48,771,227	0.85
Operating profit	27,144,596	22,368,945	0.82
Net financial income	-2,220,989	-3,017,557	1.36
Pre-tax profit	24,923,607	19,351,388	0.78
Income tax expenses	2,604,531	206,134	0.08
Net profit	22,319,076	19,145,254	0.86

Regarding the expenditures made in the first semester of 2020, the situation is:

- expenses with raw materials and consumables amounted to 66,398,931 LEI, by 15% lower than the value registered in the similar period of 2019, being correlated with the value of the performed production. The productive activity was slowed down on two manufacturing flows, where the staff is more numerous, in order to diminish the risk of infection with the SARS-COV 2 virus. The need to protect the health of employees in the context of the pandemic led to the adoption of special measures to minimize the risk of viral contamination: sanitary supplies were provided, not only to employees working in the production process, but to all our employees. This involved spending on additional consumables. The manner of making the expenses for preventing and fighting the infection with the SARS-COV 2 virus was verified by the Chamber of Accounts Iași. The Control Report proves the judicious use of resources.
- staff costs are higher by 7% compared to the value recorded in the same period of the previous year, as a result of the continuation of the project initiated in 2019 for implementing a modern hierarchy and salary system, in order to align the benefits package to the performance level of each employee.
- depreciation and amortization expenses increased by 6%, being the result of the continuous investment process in technological equipment.
- other operating expenses dropped by 15%, as a result of the cost-cutting measures.

As a result of the performed income and incurred expenses, the net profit on 30.06.2020 amounted to 19,145,254 LEI, representing 86% from the value recorded on 30.06.2019.

In the current conditions, in which the pandemic has left its mark on all the world's economies, the company will rectify the indicators approved in the Revenue & Expenditure Budget for 2020, aiming to ensure the budgetary functions, respectively: forecasting, control of financial execution and ensurance of the financial balance.

Financial Position Statement

Indicators	Financial year		30.06.2020/ 31.12.2019
	31.12.2019	30.06.2020	
0	1	2	3=2/1
ASSETS			
FIXED ASSETS			
Tangible assets	363,616,611	379,243,099	1.04
Intangible assets	16,385,709	18,062,450	1.10
TOTAL FIXED ASSETS	380,002,320	397,305,549	1.05
CURRENT ASSETS			
Stocks	73,975,988	114,080,189	1.54
Trade and similar receivables	338,159,774	272,878,955	0.81
Cash and cash equivalents	1,877,409	3,861,622	2.06
TOTAL CURRENT ASSETS	414,013,171	390,820,766	0.94
TOTAL ASSETS	794,015,491	788,126,315	0.99
LIABILITIES			
CURRENT LIABILITIES			

Commercial and similar debts	72,337,840	79,450,266	1.10
Amounts owed to credit institutions	125,875,879	109,986,199	0.87
Debts from current taxes	13,267,396	5,690,516	0.43
Subventions for investments			
TOTAL CURRENT LIABILITIES	211,481,115	195,126,981	0.92
LONG -TERM LIABILITIES			
Subventions for investments	3,079,169	2,926,024	0.95
Deferred tax	25,531,938	25,738,072	1.01
Amounts owed to credit institutions	57,080,354	68,406,475	1.20
TOTAL LONG-TERM LIABILITIES	85,691,461	97,070,571	1.13
TOTAL LIABILITIES	297,172,576	292,197,552	0.98
Share capital and reserves			
Share capital	264,835,156	264,835,156	1.00
Revaluation reserves	50,804,319	49,499,028	0.97
Legal reserves	13,426,761	13,426,761	1.00
Other reserves	200,655,367	204,149,957	1.02
Retained earnings	-56,432,683	-55,127,392	0.98
Distribution of profit	-7,269,283	0	
Current result	30,823,278	19,145,254	0.62
TOTAL EQUITY	496,842,915	495,928,763	1.00
TOTAL CAPITALS AND LIABILITIES	794,015,491	788,126,315	0.99

Patrimonial assets

Total assets on 30.06.2020 amounted to 788,126,315 LEI, a value close to the one recorded on 31.12.2019. In its structure, fixed assets increased by 5% compared to the value at the beginning of the year, due to performing investments.

As of 30.06.2020, the total current assets were higher than the value of current liabilities and the value of permanent capitals (equity + long-term debts) exceeded the value of fixed assets, which shows that the company meets the principle of aligning the maturity of assets and liabilities.

The need to ensure stocks for the continuity of sales during the revision period determined the increase of their value, compared to the value recorded on 01.01.2020.

The value of receivables was 272,878,955 LEI, lower than the one recorded on 01.01.2020, being correlated with the level of sales revenues as well as with the result of continuous measures for optimizing the commercial relations with the customers.

Patrimonial liabilities

At the end of the first semester of 2020, current liabilities recorded a value of 195,126,981 LEI, by 8% lower compared to the value at the beginning of 2020. In their structure:

- short-term loans were lower by 13%;
- debts to the suppliers increased by 10%, as a result of renegotiating contracts with suppliers by extending payment terms;
- current tax liabilities decreased by 57%.

The value of long-term debts, represented by the bank loan contracted to ensure the financing of investments in the new Ointment & Suppository Plant increased by 20% compared to the value at the beginning of the year, as a result of the intensification of the works for this investment objective. Equity is at a level similar to that recorded at the beginning of 2020.

The company does not register outstanding obligations to the state budget.

Analysis of the main economic-financial indicators

Name of indicator	Calculation formula	30.06.2019	30.06.2020
Current liquidity	Current assets / Current liabilities	2.13	2.00
Level of indebtedness	Borrowed capital / Equity x 100	28.07%	35.97%
Turnover speed for client debit items	Average customer balance / Sales revenue x Time	303 days	352 days
Fixed assets turnover	Sales revenue / Fixed assets	0.52	0.37
Net profit rate	Net profit / Sales revenue x 100	12.94	13.07

Current liquidity, which reflects the company's ability to pay short-term obligations from the current assets, is at an optimal level (according to international usage, current liquidity should be around 2).

The degree of indebtedness increased, as a result of the use of amounts from the long-term bank credit, being in line with the stage of accomplishment of the works in the new Ointment & Suppository Plant. In accordance with the clauses of the contracts, the amounts will be reimbursed starting with 2021. Turnover rate speed for client debit items and fixed assets turnover decreased, being affected by the level of sales revenues, the average balance of receivables was at a level similar to that recorded on 30.06.2019 and the value of fixed assets increased by 19% in compared to the value recorded in the similar period of the previous year.

Net profit rate, higher than the value recorded on 30.06.2019 reflects the efficient management of liquidity, assets and debts.

Amounts owed to credit institutions

Amounts owed to credit institutions on 30.06.2020 are presented in the following table:

Amounts owed to credit institutions	Value (LEI)
Amounts due in the short term	109,986,198.73
Amounts due in the long term (interest included)	68,406,475.30

Short-term contract no. IAS3-42-2016/ 17.08.2016 concluded with Unicredit Bank S.A.

Objective	Credit line - working capital
-----------	-------------------------------

Amount	55,000,000 LEI
Maturity	16.08.2020
Balance at June 30, 2020	50,930,807.68 LEI
Guaranties	Mortgage contract for buildings, land / Contract for assignment of receivables

Contract no. IAS3-20-2018/03.05.2018 concluded with Unicredit Bank S.A.

Objective	Capital investment loan
Amount	15,406,300 EUR
Maturity	02.05.2028
Balance at June 30, 2020	14,126,856.10 EUR (68,406,475.30 LEI)
Guaranties	Mortgage contract for buildings, land / Contract for assignment of receivables

Short-term contract no. 12/01.07.2013 concluded with Export-Import Bank of Romania-EXIMBANK S.A.

Objective	Credit line - working capital
Amount	30,000,000 LEI
Maturity	23.06.2021
Balance at June 30, 2020	27,312,537.01 LEI
Guaranties	Mortgage contract for buildings, land / Contract for assignment of receivables

Short-term contract no. 12239/22.05.2012 concluded with ING BANK N.V. AMSTERDAM - Romania Branch

Objective	Credit line - working capital
Amount	9,500,000 EUR
Maturity	22.05.2021
Balance at June 30, 2020	27,550,062.97 LEI 865,867.68 EUR (4,192,791.07 LEI)
Guaranties	Mortgage contract for buildings, land / Contract for assignment of receivables

SC Antibiotice SA did not submit guarantees and did not pledge, respectively did not mortgage its own assets in order to guarantee some obligations in favor of a third party.

Cash flow

On 01.01.2020, cash and cash equivalents were -123,998,470 LEI, being represented by credit lines worth 125,875,879 LEI and cash in bank accounts, from the same lines of credit, amounting to 1,877,409 LEI.

From the operating activity, the cash receipts amounted to 223,981,296 LEI. The value of cash payments to suppliers of goods and services was 103,159,929 LEI, and payments to and on behalf of employees amounted to 48,661,103 LEI.

Payments representing taxes, fees and bank interest, made in the first semester of 2020 amounted to 28,425,194 LEI. For the investment activity, payments were made in the amount of 25,805,915 LEI. On 30.06.2020, cash and cash equivalents were -106,124,577 LEI, representing credit lines amounting to 109,986,199 LEI and 3,861,622 LEI cash in bank accounts and cash remaining from the same lines of credit.

The Management Report was prepared on the basis of financial data that were audited according to legal requirements by the external financial auditor. S.O.C.E.C.C. S.R.L. Bucharest.

4. Adapting our human resources to the company's strategic directions

The 2020 performance indicators for the Human Resources Unit are set in accordance with the Business Plan of Antibiotice SA for the period 2020 - 2025. They aim the following objectives:

- Efficiency of salary expenses

The compliance with the provisions of the approved budget was monthly monitored.

Performance indicators	Planned for 6 months 2020	Achieved in the first 6 months of 2020
Average number of employees	1,415	1,415
Staff costs	50,561 thousand LEI	49,472 thousand LEI

- Non-discriminatory staffing, training of skills needed to achieve goals and increase involvement
- Reorganization and adaptation of the personnel structure on key organizational components of the company was achieved by substantiating and implementing the decisions to restructure the activities.
- Identification of the necessary personnel for each structure, in order to achieve the objectives, was made according to the new organizational charts through the detailed analysis of the personnel, retirement possibilities according to the new legal provisions and the need to attract personnel.

To ensure the necessary staff, the Human Resources Unit conducts also specific projects:

- Perform a+, the 5th edition, a project for practical training and personnel selection, through partnership with the universities.
Starting with this year, the addressability of this project was extended, in order to attract chemistry students (master students, doctoral students) of the Faculties of Chemistry within the "Al. I. Cuza" University of Iasi and the "Gheorghe

Asachi" Technical University of Iasi, due to the need for specialists within the Analytical Research activity.

Due to the limitations and restrictions imposed by the legislation from the period declared as state of emergency and state of alert, the program was postponed for the second semester of 2020, being redesigned to adapt the proposed themes to the online transmission mode.

Partnerships established with pre-university educational institutions, Petru Poni Technological High School and Technological High School of Mechatronics and Automation **Iași**, for internships in our company. In 2019, within these partnerships, the Iasi County School Inspectorate approved the organization of a dual education project that will ensure the preparation of 15 students for the profession of chemical operator for medicines and cosmetics and 10 students for the profession of electrician in the 2020-2021 school year.

- Training programs for professional and personal development of employees

The 2020 training plan with external lecturers has as objectives both continuous professional development and acquisition of knowledge and managerial skills.

Monthly trainings and attestations take place for the personnel with responsibilities regarding the technical equipment and installations: ISCIR, ANRE, INSEMEX, etc.

Starting with March 2020, in the socio-economic context of the state of emergency in Romania, we accessed online courses offered by training providers, programs that will continue in the third quarter depending on the prevention measures at national level.

- Strategies and measures to increase our employees' motivation

Following the project of ranking the positions with higher education and secondary education, based on analyzes of the current salary system compared to the similar positions in the labor market, as well as the ranking of positions based on their complexity, a program for harmonizing the salary levels was established that will take place in several stages.

The program was established by an additional act to the Collective Labor Agreement, the first stage being applied starting from January 2019 and in the second quarter of 2020 salary levels were aligned based on which the system has been adapted and includes the fixed component, based on hierarchy as well as the variable component, in direct correlation with the employees' performances.

The designated joint commissions, in accordance with the provisions of the Additional Act no. 3/2019 to the Collective Labour Contract renegotiated the clauses of the chapter 4 "Payroll. Other benefits and facilities ". The Additional Act no. 4/2020 to the Collective Labor Agreement was signed and entered into force on June 2020. This document sets an 11.5% increase in salaries, depending on the eligibility criteria and an increase in the value of the meal voucher from 12 LEI to 15 LEI.

During the state of emergency period, measures were taken to protect our employees who continued their activity on the site - free of charge transport, free meals, protection materials, and for their reward, attendance bonuses were granted.

Adapting the reward system and creating a consistent policy of financial and non-financial motivation of employees has the role of increasing employee satisfaction and improving staff retention.

The indicator “staff turnover rate due to voluntary resignations” registered in the first semester the value of 1.8 %.

- Improving the organizational climate and focusing the organizational culture towards innovation and performance

In January - June 2020, the actions provided in the plan of measures for the period 2019 - 2020 regarding the improvement of the organizational climate took place.

In order to monitor the evolution of the climate and satisfaction indicators and evaluate the results of the measures from the Action **Plan, the indicator “the degree of satisfaction of employees related to their job” will be evaluated annually** through a diagnostic study.

In June, the designed questionnaire was applied to the employees, both in printed and electronic format, their answers and opinions being processed between July and August. The project specifies as the report and plan of measures for the period 2020-2021 to be completed in September 2020.

5. Integrated quality management

Certified quality

Confidence in the quality, efficiency and safety of the company's products increases by keeping under control and improving the Integrated Management System.

Inspections conducted by authorities

During 01.01.2020-30.06.2020, no inspections of the regulatory authorities were carried out. Given the specifics of this period due to the COVID -19 pandemic, Antibiotice has adapted to the regulations and requirements of national and European authorities, in accordance with *Notice To Stakeholders-Question and Answers, on Regulatory Expectations for Medicinal Products for Human Use During Covid 19 Pandemic*, issued by the European authority.

Audits conducted by certification bodies

During the first semester of 2020, no audits of the certification bodies were carried out. The ISO 9001: 2015, ISO 14001: 2015 and ISO 45001: 2018 certificates were issued following the certification audit from 02.12.2019-05.12.2019 issued by the TUV Rheiland certification body.

Audits conducted by our customers

During the first semester of 2020, two audits took place: one on the manufacturing and control flow of Nystatin - active substance, in order to requalify the company as an API provider and one on the manufacturing and control flow of parenteral products.

Occupational health and safety

By maintaining and developing an effective occupational health and safety management system within the company we create an optimal framework for managing and eliminating work-related risks, as well as for improving the environment and the relationships between employees.

The principles and measures of the occupational safety system are established and followed, through the Prevention & Protection Plan, by the Occupational Safety and Health Committee (CSSM), organized in our company.

The Prevention & Protection Plan for 2020 includes several measures aimed at permanently improving the working conditions and prevention of work accidents and occupational diseases.

The first meeting of the Safety & Health Committee was organized and the representatives of the Work Safety Committee were consulted for identifying new professional risks as well as and all the measures included in the Prevention & Protection Plan, as follows:

- in order to reduce the physical effort, the Topical Products Division and Logistics Department were completely equipped with equipment for transporting and lifting the raw materials and finished product;
- for the prevention and reduction of risks, a multi-gas detector and a tube pump, used to measure the presence of toxic gases, were purchased at the Occupational Health and Safety Department.

In order to avoid the spread of the SARS-CoV-2 virus among employees, a series of technical and organizational measures were taken, which proved to be effective because there was no need to interrupt the company's activities:

- Nomination by the company's management of a Crisis Cell, subsequently of a Health and Safety Committee that constantly monitored, step by step, the impact and evolution of the epidemic worldwide, activated the links with the competent medical and governmental authorities so that to be able to anticipate and take the most appropriate measures, in step with the evolution of the epidemic situation at national level;
- A working procedure was drawn up, correlated with a series of training and awareness campaigns regarding the rules to be observed among employees;
- Disinfectant dispensers and disinfectant rubber mats were installed and all our employees were provided with the necessary sanitary and protective equipment on a daily basis (masks, gloves, face visors, hand and surface disinfectants, etc);
- Thermometrization of employees with thermal scanners, correlated with hand disinfection and mandatory wearing of a medical mask;
- Carrying out daily medical examinations by their own medical staff (3 doctors and 5 nurses) and isolating at home the employees with respiratory diseases;
- Periodic disinfection of traffic contact surfaces (doors, handles, valves, railings, etc.) and means of transport of persons and goods;
- Cancellation of internal business events and trips in the country and abroad;
- Limiting to the maximum the access in the company for the persons who do not have the quality of employee.

On March 15, when the virus became a health threat, the Crisis Cell developed three working scenarios with gradual plans of measures, for ensuring the safety of our employees and the production necessary for the deliveries of medicines to the distributors and hospitals in Romania.

Scenario 1, applied in our company starting with March 16, envisaged continuation of production activities, utilities, deliveries of medicines and limiting to the maximum the indirectly productive activities through the work of the employees from home (approximately 70% continued the work on the site).

In order to increase employee safety concurrently with new measures taken at national level, the Crisis Committee internally adopted additional measures: daily disinfection of employee transport buses and common areas by nebulization, increased medical checks among employees, imposing distance at the entrance to the factory (1.5 meters-2 meters) and in the work areas.

Scenario 2

Starting March 23, our company entered the second scenario which involved the complete interruption of indirectly productive activities and limitation to the maximum possible of production and service, maintaining only the activities strictly necessary to honor the orders launched by the Romanian health system and to deliver medicinal products abroad.

In the second week since the outbreak began, the Crisis Committee increased the level of security of employees' health, with new additional safety measures. Thus, wearing a mask and gloves, from the moment of boarding the transport buses and later, at work, became mandatory, traffic inside the factory was reduced to what was strictly necessary, meetings with more than three people were prohibited, at the same time with the encouragement of communication by mail, telephone and keeping a 2-meter distance at work.

Scenario 3, in which the company and its employees did not enter, involved the total interruption of the company's activities, continuing only the maintenance and security activities.

Environmental responsibility

Antibiotice has an Environmental Protection Department in charge of the pollution prevention and continuous improvement of the environmental performance, acting in order to comply with the requirements of the environmental legislation.

By obtaining the Integrated Environmental Authorization no. 1/10.01.2011, issued by the Regional Environmental Protection Agency Bacau (revised in 2018 and valid for 10-year period), Antibiotice proves that it is a company that meets the environmental requirements related to the emissions of pollutants in air, water and soil, being below the limits provided by the applicable norms in the field. Our company obtained also the Water Management Authorization no. 303/20.12.2010 issued by the National

Administration of Romanian Waters, Basin Water Administration Prut- Barlad (valid until 31.12.2020).

In the H1 2020, the acts regulating the functioning of the company were maintained, actions being started for the reauthorization on the water management and the integrated environmental authorization (development of the inquiry stage for elaboration of specific documentation by authorized entities, according to the legal requirements).

In order to comply with the environmental protection legislation, our company provided the necessary specific equipment and qualified personnel. The entire activity is regulated by operating procedures of the environmental management system and specific working instructions.

The environmental factors were monitored in H1 2020 according to the requirements of the Integrated Environmental Authorization, both through our own laboratories and through a laboratory authorized by the Romanian Accreditation Association (RENAR) for determining the values of pollutant emissions into the atmosphere from the incinerator and combustion boilers from the thermal power plant, as well as for solvent emissions from the Biosynthesis Plant. The determinations showed the observance of the requirements established by the Integrated Environmental Authorization, without exceeding the maximum allowed concentrations.

Specific consumption and use of energy

The activity developed in the Biosynthesis Plant that produces the active substance Nystatin falls within the scope of the European Directive for Integrated Pollution Prevention and Control (IPPC). In H1 2020, the Biosynthesis Plant was within the planned specific consumptions.

Air quality

In H1 2020, our own laboratory monitored the air quality conducting analyzes regarding emissions / imissions of air pollutants for nitrogen oxides, ammonia, suspended powders and sedimentable powders.

Also, we express a permanent concern for reducing the effects of emissions of technological odors, by their supervision and monitoring, as well as by using different technical solutions to limit them (filter equipment).

There were no exceedances of the maximum allowed concentrations specified in the Integrated Environmental Authorization.

Water quality

Water quality was monitored through analyzes regarding the quality of the water entered the own wastewater treatment plant and discharged into the municipal sewage system, quality of the conventional clean water discharged into the natural stream, as well as the quality of groundwater.

There were no exceedances of the maximum allowed concentrations established by the Integrated Environmental Authorization, the Water Management Authorization and H.G.R. no. 352 of 2005 (NTPA 001 and NTPA 002).

Soil protection and groundwater

From the total area of the land in the property of Antibiotice, about 40% is covered with green spaces.

Quality of the groundwater was monitored by monthly collecting and analyzing the samples obtained from the perimeter observation wells. There was no accidental pollution or environmental incident leading to the degradation of soil quality in the area of influence of the company's activity.

Waste management

Antibiotice implemented a selective waste collection system, each production plant and auxiliary activity being equipped with containers suitable for collection.

The recyclable waste were sold to the authorized economic operators.

The non-valuable waste was incinerated in our own incineration plant or stored to the municipal landfill.

Antibiotice complies with the requirements for the packaging waste management (corresponding to the quantity of packaging introduced in the market) established by the specific legislation, namely the recovery / recycling of 60% of the quantity of packaging placed in the national market.

Prevention and management of emergency situations

In our company, the prevention of emergency situations and the assurance of the intervention capacity in case of accidents are ensured through the correlated activity of the departments: Emergency situations, Environmental protection, Labour Health and Safety.

To this end, the plan for preventing and combating accidental pollution, as well as the procedure for preparing for emergencies and response capacity are being developed / updated.

Solidarity and responsibility

In the context of an atypical first semester worldwide, Antibiotice has chosen to be responsible and supportive of both the hospitals at the forefront of the SARS-CoV-2 virus, patients whose lives are in the hands of blood donors, and the elderly with vulnerabilities - former employees of the company.

Thus, in March, Antibiotice supported nine hospitals with donations in cash and medicines that were made available to them according to their needs. Financial support amounting to 600,000 LEI was for 8 hospitals from Iasi and Prof. Dr. Matei Bals National Institute of Infectious Diseases, the main pole for treating people infected with the SARS-CoV-2 virus. The 8 hospitals from Iași supported by Antibiotice are: Sfanta Parascheva Infectious Diseases Hospital, Prof. Dr. Nicolae Oblu Emergency Clinic Hospital, Sf. Spiridon **Iași** County Clinical Emergency Hospital, Prof.Dr. George I.M. Georgescu Cardiovascular Diseases Institute, Pneumoftiziology Hospital, Sfanta Maria Clinical Emergency Hospital for Children, Dr.C.I. Parhon Hospital and the Regional Oncology Institute.

Starting April, with the involvement of the “Science and Soul” Foundation, 27 former Antibiotice employees benefit periodically from an aid consisting of packages with basic products. This social responsibility project, called "Respect for the Elderly", targets our former employees, who in the past worked in the drug industry and saved lives and now have health issues, they cannot move or are alone and helpless.

The “Science and Soul” Foundation in partnership with the Regional Blood Transfusion Center (CRTS) Iași organized the 19th edition of the campaign “Donate blood! Put your soul to life! ” As part of this action, in June, 70 Antibiotice employees donated 32 liters of blood, which will save over 150 lives, thus meeting the need for life-saving blood in hospitals. The need for blood is chronic in Romanian hospitals, but during this period it is even higher as the number of donors nationwide decreased due to fears of a possible infection and restrictions during the emergency period.

The Antibiotice Center for Clinical Studies, the host of the event, allowed the action to take place in conditions of maximum safety. The team of employees of the Center ensured the observance of all the rules of sanitary hygiene and distance that are imposed in order to ensure the quality and security of the donation act. The Center for Clinical Studies is the only DSP certified center in Iași in which CRTS Iasi can collect blood.

V. Corporate governance

Corporate governance is a complex of processes, practices, policies, regulatory framework, with an impact on the management, administration and control of a company.

Corporate governance has an important role in protecting the interests of shareholders, as it supports maximizing the value of long-term ownership in the company, and in stimulating investors' attention to the company, by making the activities and processes transparent and efficient, because the investors need accurate and quality information, disseminated in time to be able to make investment decisions.

The governance system is in accordance with the provisions of Law 24/2017 on issuers of financial instruments and market operations, Law no. 31/1990 republished, with all subsequent amendments, A.S.F Regulation no. 5/2018, Law no. 111/2016 for the approval of the Government Emergency Ordinance no. 109/2011 on the corporate governance of the public enterprises, BVB Code, Corporate Governance Code of BVB and **the company's** Articles of Association.

The Antibiotice corporate governance system is based on the following pillars:

- Corporate Governance Code
- Code of Ethics
- General Meeting of Shareholders

- Management Board
- Advisory Committees
- Executive Management
- Internal audit, Inventory Financial Control and Risk Management

Corporate Governance Code

The Code of Corporate Governance of Antibiotice SA included the principles and recommendations of the Bucharest Stock Exchange and represents the tool through which Antibiotice implements these principles and recommendations.

The Corporate Governance Code creates the necessary framework for establishing strong relationships with the shareholders and other stakeholders, as well as for an effective and transparent, trust-based communication.

The Corporate Governance Code of Antibiotice SA is divided into four chapters:

Chapter I - Responsibilities of the Management Board

Chapter II - Risk Management and Internal Control System

Chapter III - Fair reward and motivation

Chapter IV - Investor relations

It also has two annexes:

Annex I - Management Board's Rules of Procedure

Annex II - **Rules for evaluating the Antibiotice's administrators**

Chapter I - Responsibilities of the Management Board - defines the role of this body while setting the guidelines in terms of competence, experience, knowledge and independence of its members, which enable them to effectively perform their specific duties and responsibilities.

Chapter II - Risk Management and Internal Control System - demonstrates that the **company's activity is supervised by certain risk management and internal control** systems set up for this purpose. Also, internal audits are conducted in order to assess independently and periodically the safety and effectiveness of the risk management and internal control systems.

Chapter III - Fair reward and motivation - establishes the general principles and conditions that are the foundation of the method for setting the level of remuneration **for the Board members and company's management team**.

Chapter IV- Investor relations - states the fact that Antibiotice must make constant efforts to provide the shareholders with updated information on events of interest to them (e.g. general meetings of shareholders, shareholder-related rights, etc).

In conclusion, The Corporate Governance Code of Antibiotice SA and its annexes draw the general framework under which the Management Board develops its activity in accordance with the rules and principles of corporate governance established by the Bucharest Stock Exchange, in order to create an attractive capital market, based on the best practices, transparency and trust.

Code of Ethics

The Code of Ethics of Antibiotice SA presents the ethical standards of conduct that establish and regulate the **corporate values, the company's business responsibilities and obligations** and how the company operates.

The Code of Ethics provides rules in the key areas relating to employees, human rights, environmental management, social responsibility and corporate governance.

The Code is binding and applies to all the structures and activities of the company.

The Code of Ethics is a fundamental commitment of our company to do its best in order to comply with the high ethical standards and applicable legal requirements wherever it operates.

The Code of Ethics is presented in detail on the website of our company:

<https://bit.ly/2oOfRHT>

General Meeting of Shareholders

The Executive Management coordinates the strategic development of the company, in close cooperation with the Management Board. Periodically, the two bodies analyze the results obtained in the implementation of the strategy according to the Business Plan, the performing criteria and the Revenue & Expenditure Budget. The Executive Management informed the Management Board in seven sessions in H1 2020 about all the significant aspects of the activity carried out and its evolution in relation to the previous forecast, presenting reports according to the agendas of the meetings. These reports were analyzed by the members of the Management Board and, based on them, as well as on other information, adopted decisions with effects in the development of the company's activities.

The Management Board represents the company in relation with the appointed directors. The President coordinates the activity of the Management Board and reports to the General Meeting of Shareholders. He oversees the proper functioning of the company. The President represents the Management Board in relations with third parties. Other attributions may be delegated to him by the Management Board. The Vice-President replaces de jure the President of the Management Board when he/she is absent (according to Art. 29, Chapter V, Articles of Association of the trading company Antibiotice - S.A, Iasi).

The Executive Management of Antibiotice Iasi is ensured by executive directors, one of whom is the General Director and Vice President of the Management Board.

General Meeting of Shareholders (GMS) represents the highest decision-making body of the company, where the shareholders participate directly in the decision-making process. Among other attributions, GMS decides the distribution of profit, elects the Management Board, appoints the auditors and sets the remuneration for the Management Board members.

In the H1 2020, the Management Board convoked 5 General Meetings of Shareholders, of which, 3 were Ordinary General Meetings (March 6; April 9; May 20, 2020) and 2 were Extraordinary General Meetings (April 9 and May 20, 2020).
All the necessary documents relating to the smooth conduct of the General Meetings were published in due time and as required by the law.

The Ordinary General Meeting of Shareholders of March 6, 2020 approved the company's Income & Expenditure Budget for 2020.

The Ordinary General Meetings of Shareholders of April 9 and May 20, 2020 approved also:

- The financial statements of the company for the financial year 2019, based on the Management Report and the Financial Auditor's Report.

Destination	Amount(LEI)
Profit to be distributed:	30.823.278
- legal reserve	0
- other profit reserves provided by law	10,763,873
- dividends, of which:	20,059,405
- dividends due to the majority shareholder	10,634,950
- dividends due to other legal entities and individuals	9,424,455

- the value of the gross dividend per share for the financial year 2019 is 0.029879738 LEI. The payment of dividends for 2019 will be made starting with 21.09.2020, according to the legal provisions in force;
- registration as income of unsolicited and uncollected dividends, related to the financial year 2015;
- the degree of achievement of the objectives and performance criteria for 2019, for the Management Board members;
- the discharge of administration for the activity conducted in the fiscal year 2019, based on reports submitted;
- **objectives of the Management Board's members set in the 2020 Administration Plan;**
- **setting the remuneration of the Management Board's** members, according to the provisions of GEO no. 109/2011 on the corporate governance of public enterprises and GD no. 722/2016 for the approval of the Methodological Norms for the application of certain provisions of the Government Emergency Ordinance no.109 / 2011 on the corporate governance of public enterprises;
- appointment of the SOCECC company as an external audit company for a 3-year period;
- appointment of Ms. Elena Calitoiu and Mr. Nicolae Stoian as non-executive directors, for a 4 (four)-year term starting with the date of April 18, 2020, in accordance with the procedures established by art. 29 of the GEO. no. 109/2011 on the corporate

governance of public enterprises and their mandate contracts for the period 18.04.2020 - 17.04.2024.

- renewal of the executive administrator's mandate for Mr. Ioan Nani for the period 01.06.2020 - 18.04.2024 as well as signing the additional act to the mandate contract no. 3186 P of 09.04.2020.
- appointment of Mr. Lucian Timofticiuc as an interim administrator for a 4-month period, with the possibility of extension up to 6 months for good reasons, as well as signing the mandate contract;
- initiation of the selection procedure for an administrator position that has become vacant as a result of the resignation of Mr. Cristian Vasile Grasu, pursuant to art. 64¹ and art. 64⁴ of GEO no. 109/2011 regarding the corporate governance of public enterprises and art. 4 of Annex no. 1 to GD no. 722/2016 for the approval of the Methodological Norms for the application of some provisions of the Government Emergency Ordinance no. 109/2011 regarding the corporate governance of public enterprises, as well as the empowerment of the Management Board for the application of the selection procedures established by art. 29 para. 2 of GEO no. 109/2011 regarding the corporate governance of public enterprises;
- the registration date 31.08.2020 for the identification of the shareholders affected by the effects of the decisions adopted, in accordance with the provisions of art. 86, para. 1 of Law 24/2017 on issuers of financial instruments and market operations, and the establishment of ex-dates for 28.08.2020.

The Extraordinary General Meetings of Shareholders approved:

- a 12-month extension of the validity period of the multicurrency multiproduct credit amounting to 30 million LEI borrowed by SC Antibiotice SA from the Export Import Bank of Romania- Eximbank S.A..
- to maintain the guaranties related to the multi-product multi-currency credit amounting to 30 million LEI throughout the validity period (one calendar year starting with 26.06.2019) resulting from the extension under point 1 of the Agenda;
- to issue a decision-commitment of Antibiotice not to divide itself, not to merge and decide the anticipated dissolution throughout the entire validity period of the multi-product multicurrency credit without the prior consent of the Export-Import Bank of Romania - EximBank SA..
- to empower the General Director Mr. Ioan NANI and Financial Director Ms. Paula COMAN to sign on behalf of the company all documents related to the credit facility extension under paragraphs 1 and 2 of the Agenda, as well as documents related to obligations assumed by the company in accordance with paragraphs 3 of the Agenda.

Management Board

Antibiotice is administered by a Management Board responsible for fulfilling all the tasks necessary **to achieve the company's object of activity, except those provided by law** for the General Meeting of Shareholders. There is a clear division of responsibilities between the Management Board and Executive Management.

The Management Board aims as its own decisions, those of the company's management and of the General Meeting of Shareholders as well as the internal regulations be compliant with the legal requirements and properly implemented. The Board is responsible for monitoring the company's management on behalf of the shareholders. The duties of the Management Board are described in the company's Articles of Association and in the relevant internal regulations available on our company's website under the *Corporate Governance* section.

Management Board of Antibiotice SA on June 30, 2020

Dan Octavian Alexandrescu, Physician, 45 years old
President of the Management Board and representative of the Ministry of Health
Non-Executive, Independent Administrator
At the Ordinary General Meeting of Shareholders held on September 25, 2018, Mr. Alexandrescu was elected as a member of the Management Board in accordance with the provisions of art. 64¹ of GEO no. 109/2011.
Mr. Dan-Octavian Alexandrescu is a physician at C. I. Parhon National Institute of Endocrinology, Bucharest
Number of Antibiotice SA shares held - 0*

Ioan Nani, Economist, 60 years old
VicePresident of the Management Board and General Director
Permanent Executive Administrator
At the Ordinary General Meeting of Shareholders held on May 20, 2020, Mr. Nani was reconfirmed as a member of the Management Board, for a 4-year period, the members of the Management Board **electing him as the Board's Vice President** on May 20, 2020.
Mr. Nani is an economist specialized in management and chartered accountant, member of the Management Board since 2009 and General Director (1998 - 2008 and 2009 - present).
Number of Antibiotice SA shares held - 1,513*

Elena CALITOIU, Engineer, 57 years old
Member of the Management Board and representative of the shareholder SIF Oltenia and other shareholders - legal entities
Permanent Non-Executive Administrator
At the Ordinary General Meeting of Shareholders held on April 18, 2020, Ms. Calitoiu was confirmed as a member of the Management Board, for a 4-year period.
Ms. Calitoiu is a mechanical engineer and Director of Placements & Risk Management Department, SIF Oltenia
Number of Antibiotice SA shares held - 0*

Nicolae STOIAN, Economist, 63 years old

Member of the Management Board and representative of the shareholder SIF Oltenia and other shareholders - legal entities
Permanent Non-Executive Administrator

At the Ordinary General Meeting of Shareholders held on April 18, 2020, Mr. Stoian was elected as a member of the Management Board for a 4-year period.

Mr. Stoian is a chartered accountant, tax consultant and financial auditor, representative of the Internal Control Department at SIF Oltenia.

Number of Antibiotice SA shares held - 0*

Lucian Timofticiuc, physicist, 45 years old

Member of the Management Board and representative of the Ministry of Health
Interim Non-Executive Administrator

At the Ordinary General Meeting of Shareholders held on May 20, 2020, Mr. Timofticiuc was elected as a member of the Management Board in accordance with the provisions of art. 64¹ of GEO no. 109/2011

Mr. Lucian Timofticiuc currently holds the position of Administrator and General Director at Vremea Noua.

Number of Antibiotice SA shares held - 0*

Advisory committees

The specialized advisory committees in H1 2020:

- *Audit Committee*: Mr. Lucian Timofticiuc, Mr. Nicolae Stoian and Ms. Elena Calitoiu;
- *Nomination and Remuneration Committee*: Ms. Elena Calitoiu and Mr. Dan-Octavian Alexandrescu;
- *Trade Policy Committee*: Mr. Lucian Timofticiuc and Mr. Nicolae Stoian.

The Advisory Committees carried out investigations, analyzes and elaborated recommendations for the Management Board in the specific fields and submitted periodically reports on their activity to the Management Board.

Internal control

The specialized internal control provided by the legislation in force is carried out by our own Internal Audit Office which carries out the following activities: internal audit, management control carried out in a methodological and procedural framework regulated by laws, norms and codes of professional conduct specific to each activity.

The way of setting and achieving the objectives of the Internal Audit Office, the findings and recommendations resulting from all the internal control actions are presented quarterly to the Audit Committee within the Management Board, for assessing the activity and internal control exercised in the company.

Risk management

Our company complies with applicable legal and regulatory requirements for identifying, assessing, managing and reporting the risks:

- Government Secretary General Order (OSGG) no. 400/2015 modified and completed by OSGG no. 200/2016 and OSGG no. 600/2018;
- Requirements of the Corporate Governance Code of the Bucharest Stock Exchange.

The main purpose of risk management is to help people understand and identify the risks to which the organization is exposed so that they can anticipate and manage these risks without compromising the organization's effectiveness.

Antibiotice objectives on risk management:

- to understand the risks to which our company is exposed as well as their general and specific causes;
- to improve the risk profile of our company by managing the process of identifying, evaluating and managing risks and by implementing the control measures needed to maintain exposure to risk within the tolerable area.

The responsibilities regarding the risk management are fulfilled by the Risk Management **Department together with the Antibiotice's risk managers and employees.**

Our Risk Management Department annually analyzes and prioritises the significant risks that may affect the achievement of the company's overall goals, by establishing the risk profile and tolerance limit approved by the management of the company. They also draw up the "Plan for implementing the control measures for significant risks related to **our company's business**" and submit it for approval to the **General Director.**

Antibiotice SA continuously re-evaluates its existing risk portfolio, identifying new exposures and adding value to the company by properly applying the best and most effective risk strategies.

Executive management

Antibiotice is represented by the General Director, according to the powers provided by **law and by the company's Articles of Association.** The Management Board represents the company in relationship with the appointed directors.

The Executive Management of Antibiotice is ensured by eleven directors. One of them is the General Director who is also the Vice-President of the Management Board and ten specialty executives.

VI Conclusions:

- 50% of the total sales revenue are represented by the value of sales revenue in the foreign market;
- In the domestic market, the net value of sales was 72.4 million LEI, in trend with the evolution of the pharma market affected by the reduction of drug consumption in hospitals and pharmacies;
Efficient measures for the protection of employees and business that lead to the profitable continuity of the activity;
- a balanced evolution of the income-expenditure-profit indicators has been maintained compared to 2019, in economic crisis conditions;
- reliable partner by supporting health systems in Romania and in all the ATB territories.

General Director,
Ioan Nani

Financial Director,
Paula Coman

ANTIBIOTICE S.A.

June 30, 2020 Financial statements,
drafted in accordance with the
International Financial Reporting Standards
(IFRS) adopted by the European Union

ANTIBIOTICE S.A.
Financial statements for the year ended on
June 30, 2020

Table of contents

STATEMENT OF THE COMPREHENSIVE INCOME	3
STATEMENT OF THE FINANCIAL POSITION.....	4
CASH FLOW STATEMENT	6
STATEMENT OF CHANGES IN EQUITY	8
EXPLANATORY NOTES TO FINANCIAL STATEMENTS:	9
1. GENERAL INFORMATION.....	9
2. ACCOUNTING POLICIES	Error! Bookmark not defined.
3. FINANCIAL INSTRUMENTS AND RISK MANAGEMENT	28
4. SALES INCOME	Error! Bookmark not defined.
5. OTHER OPERATING INCOME	33
6. RAW MATERIALS, CONSUMABLES AND GOODS	Error! Bookmark not defined.
7. STAFF-RELATED EXPENSES	33
8. OTHER OPERATING EXPENSES	33
9. FINANCIAL INCOME AND FINANCIAL EXPENSES	34
10. EXPENDITURE ON CURRENT AND DEFERRED PROFIT TAX AND OTHER TAXES.....	Error! Bookmark not defined.
11. EARNINGS PER SHARE.....	Error! Bookmark not defined.
12. TANGIBLE ASSETS	Error! Bookmark not defined.
13. INTANGIBLE ASSETS	Error! Bookmark not defined.
14. STOCKS	37
15. TRADE AND OTHER RECEIVABLES	Error! Bookmark not defined.
16. CASH AND CASH EQUIVALENTS	Error! Bookmark not defined.
17. TRADE AND OTHER LIABILITIES.....	Error! Bookmark not defined.
18. AMOUNTS DUE TO CREDIT INSTITUTIONS	Error! Bookmark not defined.
19. SUBSIDIES FOR INVESTMENTS	41
20. DEFERRED INCOME TAX.....	Error! Bookmark not defined.
21. SHARE CAPITAL.....	Error! Bookmark not defined.
22. RESERVES	Error! Bookmark not defined.
23. RETAINED EARNINGS.....	43
24. CONTINGENT LIABILITIES.....	43
25. ELEMENTS FOLLOWING THE REPORTING PERIOD.....	Error! Bookmark not defined.
26. INFORMATION ABOUT THE AUDIT OF FINANCIAL STATEMENTS.....	Error! Bookmark not defined.

ANTIBIOTICE SA
STATEMENT OF THE COMPREHENSIVE PROFIT

For the year ended on June 30, 2020

(all amounts are expressed in LEI, if not mentioned otherwise)

		For the year ended on	
	NOTE	30-06-20	30-06-19
Sales revenues	4	146,377,930	172,391,095
Other operating revenues	5	22,243,720	18,686,567
Revenues relative to costs of product stocks		26,727,927	26,243,033
Capitalized income generated by the entity's activity		3,295,615	2,568,485
Expenses with raw materials and consumables	6	(66,398,931)	(78,018,365)
Staff-related expenses	7	(50,146,132)	(46,888,473)
Expenditure on amortization and depreciation		(10,959,958)	(10,329,494)
Other operating expenses	8	(48,771,227)	(57,508,252)
Operating profit		22,368,945	27,144,596
Financial income	9	72,563	43,909
Financial expenses	9	(3,090,120)	(2,264,898)
Pre-Tax Profit		19,351,388	24,923,607
Current income tax expense and other expenses	10	(206,134)	(2,604,531)
Profit		19,145,254	22,319,076
Total overall result		19,145,254	22,319,076
Earnings per share	11	0.0285	0.0332

The explanatory notes from 1 to 26 are an integrating part of the financial statements

Approved by the Management Board on 11.08.2020
and signed on behalf of:

Drafted by:

General Manager,
Mr. Ioan NANI

Financial Director,
Mrs. Paula COMAN

ANTIBIOTICE SA
STATEMENT OF THE FINANCIAL POSITION

For the year ended on June 30, 2020

(all amounts are expressed in LEI, if not mentioned otherwise)

	NOTE	30-06-20	31-12-19
ASSETS			
FIXED ASSETS			
Tangible fixed assets	12	379,243,099	363,616,611
Intangible fixed assets	13	18,062,450	16,385,709
TOTAL FIXED ASSETS		397,305,549	380,002,320
CURRENT ASSETS			
Stocks	14	114,080,189	73,975,988
Trade and similar receivables	15	272,878,955	338,159,774
Cash and cash equivalents	16	3,861,622	1,877,409
TOTAL CURRENT ASSETS		390,820,766	414,013,171
TOTAL ASSETS		788,126,315	794,015,491
LIABILITIES			
CURRENT LIABILITIES			
Trade and similar liabilities	17	79,450,266	72,337,840
Amounts due to credit institutions	18	109,986,199	125,875,879
Liabilities from current taxes and fees		5,690,516	13,267,396
Subsidies for investments	19	-	637,008
TOTAL CURRENT LIABILITIES		195,126,981	211,481,115
LONG-TERM LIABILITIES			
Subsidies for investments	19	2,926,024	3,079,169
Deferred tax	20	25,738,072	25,531,938
Amounts due to credit institutions	18	68,406,475	57,080,354
TOTAL LONG-TERM LIABILITIES		97,070,571	85,691,461
TOTAL LIABILITIES		292,197,552	297,172,576

The explanatory notes from 1 to 26 are an integrating part of the financial statements

Approved by the Management Board on 11.08.2020
and signed on behalf of:

Drafted by:

General Manager,
Mr. Ioan NANI

Financial Director,
Mrs. Paula COMAN

ANTIBIOTICE S.A.
STATEMENT OF THE FINANCIAL POSITION (continued)
on June 30, 2020
(all amounts are expressed in LEI, if not mentioned otherwise)

	NOTE	30-06-20	31-12-19
Share capital and reserves			
Share capital	21	264,835,156	264,835,156
Reevaluation reserves	22	49,499,028	50,804,319
Legal reserves	22	13,426,761	13,426,761
Other reserves	22	204,149,957	200,655,367
Reported result	23	(55,127,392)	(56,432,683)
Distribution of profit	24	0	(7,269,283)
Current result		19,145,254	30,823,278
TOTAL EQUITY		495,928,763	496,842,915
TOTAL EQUITY AND LIABILITIES		788,126,315	794,015,491

The explanatory notes from 1 to 26 are an integrating part of the financial statements

Approved by the Management Board on 11.08.2020
and signed on behalf of:

Drafted by:

General Manager,
Mr. Ioan NANI

Financial Director,
Mrs. Paula COMAN

ANTIBIOTICE S.A.
CASH FLOW STATEMENTS

For the year ended on June 30, 2020

(all amounts are expressed in LEI, if not mentioned otherwise)

	30-06-20	30-06-19
I. Cash flows from operating activities		
Cash collection from the sales of goods and provision of services	223,981,296	185,978,184
Cash collection from royalties, fees, charges and other revenue	294,112	141,706
Cash payment to suppliers of goods and services	(103,159,929)	(97,107,286)
Cash payments to and on behalf of employees, payments made by the employer for its employees	(48,661,103)	(44,735,633)
VAT paid	-	-
Contributions to the Ministry of Health and the Ministry of the Environment	(22,649,854)	(21,603,991)
Other duties, taxes, and similar levies	(1,201,993)	(473,932)
Operating cash flow	48,602,530	22,199,049
Interest charged	1,143	5,030
Interest paid	(2,816,936)	(2,166,476)
Income tax / dividends paid	(1,756,412)	(238,988)
Net cash flows from operating activities	44,030,325	19,798,614
II. Cash flows generated by investments		
Cash payments for purchasing land and fixed assets, intangible assets and other long-term assets	(25,805,915)	(23,853,327)
Net investment cash flow	(25,805,915)	(23,853,327)
III. Cash flows from financing activities		
Receipts from long-term loans/reimbursements	10,476,967	5,486,028
Dividends paid	(10,659,734)	(3,610,740)
Net cash flows from financing activities	(182,766)	1,875,288
Gains/losses from exchange rate differences	(167,750)	(382,798)
Net increase/(decrease) in cash	17,873,893	(2,562,223)
Cash and cash equivalents at the beginning of the period	(123,998,470)	(98,352,547)
Cash and cash equivalents at the end of the period	(106,124,577)	(100,914,770)
The cash and cash equivalents at the end of the period include:		
Accounts in banks and cash	3,861,622	3,612,663
Credit lines	(109,986,199)	(104,527,433)

The explanatory notes from 1 to 26 are an integrating part of the financial statements

Approved by the Management Board on 11.08.2020
and signed on behalf of:

Drafted by:

General Manager,
Mr. Ioan NANI
COMAN

Financial Director,
Mrs. Paula

ANTIBIOTICE S.A.
MODIFICATIONS OF EQUITY

For the year ended on June 30, 2020

(all the amounts are expressed in LEI, if not mentioned otherwise)

	Subscribed capital	Capital adjustments	Reserves	Other reserves	Current result	Result from revaluation reserves	Profit distribution	Revaluation reserves	Reported result from the correction of errors	Result following applying IAS/IFRS for the first time	Result following applying IAS 29 for the first time	TOTAL
31-12-19	67,133,804	197,701,352	13,426,761	200,655,367	30,823,278	17,422,314	(7,269,283)	50,804,319	-	123,846,355	(197,701,352)	496,842,915
Current global result	-	-	-	-	19,145,254		-	-		-	-	19,145,254
Reserve from revaluation												-
Deferred tax relative to the revaluation difference	-	-	-	-	-		-			-	-	-
Result of error correction												-
Total other items of the global result					19,145,254							19,145,254
Transfer of reevaluation surplus						1,305,291		(1,305,291)				
Allotment of other reserves *	-	-	-	3,494,590	(3,494,590)						-	
Dividends	-	-	-		(27,328,688)		-	-		-	-	(27,328,688)
												-
Mandatory distributions					-		7,269,283					7,269,283-
30-06-20	67,133,804	197,701,352	13,426,761	204,149,957	19,145,254	18,727,605	-	49,499,028	-	123,846,355	(197,701,352)	495,928,763

The explanatory notes from 1 to 26 are an integrating part of the financial statements

ANTIBIOTICE S.A.
MODIFICATIONS OF EQUITY

For the year ended on June 30, 2020

(all the amounts are expressed in LEI, if not mentioned otherwise)

	Subscribed capital	Capital adjustments	Reserves	Other reserves	Current result	Result from revaluation reserves	Profit distribution	Revaluation reserves	Reported result from the correction of errors	Result following applying IAS/IFRS for the first time	Result following applying IAS 29 for the first time	TOTAL
31-12-18	67,133,804	197,701,352	13,426,761	190,422,002	34,303,788	14,205,380	(23,537,290)	53,459,596	(1,094,738)	124,408,011	(197,701,352)	472,727,315
Current global result	-	-	-	-	30,823,278		-	-		-	-	30,823,278
Reserve from revaluation												
Deferred tax relative to the revaluation difference	-	-	-	-	-		-			-	-	
Result of error correction							(1,094,738)		1,094,738			
Total other items of the global result					30,823,278		(1,094,738)		(1,094,738)			30,823,278
Transfer of reevaluation surplus						3,216,934		(2,655,277)		(561,656)		-
Allotment of other reserves	-	-	-	2,964,082	(27,596,110)		24,632,028	-			-	-
Dividends	-	-	-	-	(6,707,678)		-	-		-	-	(6,707,678)
Mandatory distributions				7,269,283	-		(7,269,283)					-
31-12-19	67,133,804	197,701,352	13,426,761	200,655,367	30,823,278	17,422,314	(7,269,283)	50,804,319	-	123,846,355	(197,701,352)	496,842,915

The explanatory notes from 1 to 26 are an integrating part of the financial statements

ANTIBIOTICE S.A.
EXPLANATORY NOTES TO THE FINANCIAL STATEMENTS

For the year ended on 30 June, 2020
(all the amounts are expressed in LEI, if not mentioned otherwise)

1. GENERAL INFORMATION

1.1 Brief company profile

Antibiotice SA, based in the city of Iasi, Valea Lupului street no. 1, tax registration code RO 1973096 was founded in 1955 and was defined as a trading company as per Law 15/1990 and Government Decision no. 1200/12.11.1990. Its shares are traded on the regulated capital market of the Bucharest Stock Exchange (BVB).

Our company's 8 manufacturing lines, upgraded and certified according to the Good Manufacturing Practice (GMP) standards, produce medicinal products in 5 dosage forms: powders for injectable solutions and suspensions (penicillins), capsules, tablets, suppositories and topical preparations (ointments, gels and creams). Altogether they form a complex portfolio of more than 150 medicinal products for human use designed to treat a wide range of infectious, dermatological, cardiovascular, digestive tract or musculoskeletal system diseases.

All production capacities owned by our company are located to the headquarters. The Company owns the right to ownership of all the fixed assets registered in the company's accounts.

1.2 Corporate Governance

The Antibiotice's governance system is based on:

- General Meeting of Shareholders;
- Management Board;
- Advisory Committees;
- Executive Management.

General Meeting of Shareholders

The General Meeting of Shareholders (GMS) is the company's highest decision-making body, the place where shareholders participate directly and make decisions. Among other attributions, the GMS decides upon the distribution of the profit, appoints the Management Board and the auditors and establishes the remuneration of the Management Board.

During the first semester of 2019, the Management Board convened five General Meetings of Shareholders of which three were Ordinary General Meetings (on March 6, April 9 and May 20, 2020).

All the necessary documents related to the smooth running of the General Meetings were published in due time and according to the legislation in force.

Within the Ordinary General Meeting of Shareholders on March 6, the Company's Revenue and Expenditure Budget for 2020 was approved.

The **Ordinary General Meetings** of April 9 and May 20 2020 approved:

- The financial statements of the Company for the financial year 2019, based upon the Management Report and the Financial Auditor's Report.

ANTIBIOTICE S.A.
EXPLANATORY NOTES TO THE FINANCIAL STATEMENTS

For the year ended on 30 June, 2020
(all the amounts are expressed in LEI, if not mentioned otherwise)

Destination	Amount (lei)
Profit to be distributed:	30,823,278
- legal reserve	0
- other profit reserves provided by law	10,763,873
- dividends of which:	20,059,405
- dividends due to the majority shareholder	10,634,950
- dividends due to other legal entities and individuals	9,424,455

- The value of the gross dividend per share for the financial year 2019 is 0.029879738 lei. The payment of the dividends related to 2019 will be made starting with 21.09.2020, according to the legal provisions in force;
- The registration as income of unclaimed and uncollected dividends for the financial year 2015;
- The degree in which the Management Board members achieved their objectives and performance criteria for 2019;
- The discharge of the administrators of any liability for the activity carried out during the financial year 2019, based on the submitted reports;
- The objectives included in the management plan for the Management Board members for the year 2020;
- The remuneration of the members of the Management Board according to the provisions of GEO no. 109/2011 on the corporate governance of public enterprises and GD no. 722/2016 for the approving of the Methodological norms for applying some provisions of GEO no. 109/2011 on the corporate governance of public enterprises;
- The appointment of the company SOCECC as an external audit company, for a period of 3 years;
- The appointment of Mrs. Elena CALITOIU and Mr. Nicolae STOIAN as non-executive directors, for a term of 4 (four) years starting with April 18, 2020, in accordance with the procedures established by art. 29 of the G.E.O. no. 109/2011 on the corporate governance of public enterprises and the mandate contracts of each for the period 18.04.2020 - 17.04.2024.
- The renewal of the mandate of executive administrator of Mr. Ioan NANI for the period 01.06.2020 – 18.04.2024 as well as the signing of the addendum to the mandate contract no. 3186 P from 09.04.2020.
- The appointment of Mr. Lucian Timofticiuc as a provisional administrator for a period of 4 months, with the possibility of extension up to 6 months for good reasons, as well as the signing of the mandate contract;
- The initiation of the selection procedure for an administrator position that became vacant as a result of the resignation of the administrator, Mr. Cristian Vasile GRASU, pursuant to art. 64¹ and art. 64⁴ of GEO no. 109/2011 on the corporate governance of public enterprises and art. 4 of Annex no. 1 to GD no. 722/2016 for the approval of the Methodological Norms for the application of some provisions of the Government Emergency Ordinance no. 109/2011 on the corporate governance of public enterprises, as well as the empowerment of the management board for the application of the selection procedures established by art. 29 paragraph 2 of GEO no. 109/2011 on corporate governance of public enterprises;

ANTIBIOTICE S.A.
EXPLANATORY NOTES TO THE FINANCIAL STATEMENTS

For the year ended on 30 June, 2020

(all the amounts are expressed in LEI, if not mentioned otherwise)

- The registration date **31.08.2020**, for the identification of the shareholders affected by the effects of the decisions adopted, in accordance with the provisions of art. 86, paragraph 1 of Law 24/2017 on issuers of financial instruments and market operations, and the establishment of ex-dates for **28.08.2020**.

The Extraordinary General Meeting of Shareholders approved the following:

- the extension of the validity of the multi-product multi-currency credit facility of 30 million LEI contracted by SC ANTIBIOTICE SA from the Export Import Bank of Romania - EximBank SA.
- maintaining the guarantees for the multi-product multi-currency credit facility in the amount of 30 million LEI for the entire validity period (a calendar year starting with 26.06.2019) resulting from the extension under item 1 of the Meeting's Agenda;
- the issuance of a decision-commitment of SC Antibiotice SA not to divide, not to merge and not to decide on the early dissolution during the entire validity period of the multi-product multi-currency credit facility without the prior consent of the Export Bank of Romania - EximBank SA;
- the empowerment of the General Manager Mr. Ioan NANI and of the Financial Director Mrs. Paula COMAN to sign on behalf of the company all the documents related to the extension, under the items 1 and 2 on the Agenda, as well as the documents related to the obligations assumed by the company according to point 3 of the Agenda;

Antibiotice SA in the capital market

Investors (*according to the Shareholders' Register on 30.06.2020*)


- Ministry of Health (*) – 53.0173%,
- S.I.F. Oltenia(*) - 18.9645%
- Broadhurst Investments Limited – 4.1977%
- S.I.F. Transilvania – 3.2632%
- S.I.F. Banat-Crisana S.A – 2.1104%
- A-Invest – 0.6846%
- The Privately Managed Pension Fund ARIPI/GENERALI S.A.F.P.P. – 0.6782%
- The Privately Managed Pension Fund METROPLITAN LIFE – 0.4689%
- FDI BT MAXIM ADM. BT ASSET MANAGEMENT SAI S.A. – 0.3947%
- S.C. DEDEMAN S.R.L. – 0.3407%
- Other individuals and legal entities – 15.8798%.

II. Classes of shareholders:

- Legal entities – 86.7881%
- Natural persons – 13.2119%.

ANTIBIOTICE S.A.
EXPLANATORY NOTES TO THE FINANCIAL STATEMENTS

For the year ended on 30 June, 2020
(all the amounts are expressed in LEI, if not mentioned otherwise)



- Ministry of Health – 53.0173%
- S.I.F. Oltenia(*) - 18.9645%
- Broadhurst Investments Limited – 4.1977%
- S.I.F. Transilvania – 3.2632%
- S.I.F. Banat-Crisana S.A – 2.1104%
- A-Invest – 0.6846%
- The Privately Managed Pension Fund ARIPI/GENERALI S.A.F.P.P. – 0.6782%
- The Privately Managed Pension Fund METROPLITAN LIFE – 0.4689%
- FDI BT MAXIM ADM. BT ASSET MNAGEMENT SAI S.A. – 0.3947%
- S.C. DEDEMAN S.R.L. – 0.3407%
- Other individuals and legal entities – 15.8798%.

Dividends

During the first semester of 2020, 10,404,214 shares were traded, worth 43.,37 lei (8,988 euro, 9,873 \$), with an average price of 0.5123 lei/share.

During the first six months of the year 2020, dividends were paid for the financial years 2016, 2017 and 2018 amounting to 24,783.50 lei, as follows:

Dividend history (2016-2017-2018)

Year	Net dividends							Suspension date of dividend payment
	Due	Paid				Unclaimed on 30.06.2020		
		lei			% (total paid)			
		Until 31.12.2019	01.01÷30.06.2020	Total		lei	%	
0	1	2	3	4	5	6	7	8
2016	25,401,595	23,378,774.48	10,289.53	23,389,064.01	92.08	2,012,530.99	7.92	Payment in progress
2017	17,588,679.97	16,138,163.67	9,160.36	16,147,324.03	91.81	1,441,356.07	8.19	Payment in progress
2018	6,612,624.05	6,055,864.22	5,333.61	6,061,197.83	91.66	551,426.22	8.34	Payment in progress

For the years 2016, 2017 and 2018 the dividend payment is made through the Central Depository of Bucharest and, implicitly, through CEC Bank.

Price per share evolution

ANTIBIOTICE S.A.
EXPLANATORY NOTES TO THE FINANCIAL STATEMENTS

For the year ended on 30 June, 2020
(all the amounts are expressed in LEI, if not mentioned otherwise)

The titles issued by Antibiotice have been listed in the PREMIUM category of the Bucharest Stock Exchange under the ATB symbol since 1997.

The first transaction was registered on April 16, 1997, at a reference price of 0.3500 LEI/share. The historical maximum was reached on July 10, 2007, with the price of 2.1700 LEI/share, and the historical minimum of 0.0650 LEI/share was registered on June 8, 2000.

Both the Company's business plans and financial results have been a solid guarantee that Antibiotice has strengthened its position on the national pharmaceutical market.

The shares of Antibiotice are included in the BET-Plus indices (it includes Romanian companies listed on the BSE market that meet the minimum selection criteria except for financial investment companies), **BET-XT®** (BUCHAREST EXCHANGE TRADING EXTENDED INDEX) - reflects the evolution of the prices of those 25 most traded companies on the Regulated Market of BSE, including the financial investment companies (SIFs) and **BET-XT-TR** (is the total return version of the BET-XT index, which includes the 25 most traded Romanian companies listed on the BSE). The BET-XT-TR index reflects both the evolution of the prices of the component companies and the dividends they provide.

During the first semester of 2020, the minimum price of the ATB share was worth 0.5100 lei. The share price increased to the maximum value of 0.5500 lei / share.

The stock market capitalization of Antibiotice on June 30, 2020 was 359,166 thousand lei. During this period, 10,404,214 shares were traded, amounting to 43,337 lei (8,988 euros, \$ 9,873), with an average price of 0.5123 lei / share.

Antibiotice shares – ATB/ REGULAR MARKET

	2016	2017	2018	2019	Sem. I 2020
Number of shares	671,338,040	671,338,040	671,338,040	671,338,040	671,338,040
Stock market capitalization (thousand lei)*	349,096	361,180	326,942	341,040	359,166
Stock market capitalization (thousand euro)*	76,875	77,511	70,100	71,370	74,173
Stock capitalization (thousand \$)*	81,123	92,813	80,259	79,873	83,077
Total traded value (million lei)	6	12	9	15	0,4
No. of traded shares	12,555,866	21,113,565	17,109,263	30,364,292	855,903
Opening price (lei/share)	0,5320	0.5200	0.5780	0.4800	0.5400
Maximum price (lei/share)	0,5420	0.5920	0.5780	0.5260	0.5500
Minimum price (lei/share)	0,4200	0.5200	0.4550	0.4500	0.5100
Price at the end of the period (lei/share)	0,5270	0.5380	0.4870	0.5080	0.5350
Average price (lei/share)	0,5032	0.5585	0.5028	0.4851	0.5294

* Calculated based upon the share price in the last trading day of the period

ANTIBIOTICE S.A.
EXPLANATORY NOTES TO THE FINANCIAL STATEMENTS

For the year ended on 30 June, 2020

(all the amounts are expressed in LEI, if not mentioned otherwise)

Rights of financial instruments holders

The corporate governance framework adopted and applied:

- protects the shareholders' rights,
- ensures the fair treatment of all shareholders,
- recognizes the role of third parties with interests in the company,
- guarantees the information and transparency,
- guarantees the responsibility of the Management Board towards the company and the shareholders.

On the company's website there is a section dedicated to shareholders (www.antibiotice.ro/investitori/informatiiactionari) where each shareholder can access and download documents related to the General Shareholders' Meetings: procedures regarding the access and participation in the meetings, the convocation, additions to the agenda, informative materials, special representation proxies, correspondence voting forms, draft decisions, decisions, voting results, etc.

Antibiotice makes available to all interested persons the periodical and annual financial statements prepared according to the legislation in force. The company also complies with all disclosure requirements under the legislation of commercial companies and the capital market.

Within the company there is a structure specialized in the relationship with the existing and potential investors, called Investor Relations, with the main role of implementing and monitoring the standards of corporate governance within the company, informing the shareholders and investors in accordance with the legal provisions and providing a proactive communication focused on the information needs of investors.

The persons appointed to keep in touch with the investors deal with the shareholders' requests with maximum efficiency and facilitate their dialogue with the management of the company. The company creates and develops an appropriate policy to promote an effective communication with investors and shareholders.

Antibiotice SA – member of ARIR

As it is always oriented towards the development and the increase of the transparency towards the shareholders, in completing the strategy of improving the quality of the relationship with the investors and of the desire to create value for the shareholders, on July 31, 2019, Antibiotice joined the Romanian Investor Relations Association (ARIR), a new and lively community of the Romanian capital market.

The Romanian Investor Relations Association (ARIR) is a non-governmental and non-profit organization that was established in order to provide current and potential issuers a platform for developing professionals in the field of investor relations (IR) and to contribute to implementing the best practices in communicating with investors and the corporate governance.

For the activity of investor relations as well as for the degree of transparency, accuracy and completeness of the information and accessibility of the Antibiotice website, on a scale of 1 to 10, the company was awarded **10**, granted by the Association for Investor Relations on the Romanian Stock Exchange, which evaluated 78 issuers on the Romanian capital market.

ANTIBIOTICE S.A.
EXPLANATORY NOTES TO THE FINANCIAL STATEMENTS

For the year ended on 30 June, 2020

(all the amounts are expressed in LEI, if not mentioned otherwise)

The company achieved this performance by meeting the need for the knowledge of the Antibiotice business by investors, analysts, brokers, journalists with a greater openness, approaching new and efficient communication tools.

Management Board

Antibiotice SA is managed by a Management Board responsible for carrying out all the tasks necessary to achieve the object of the company's activity, except for those provided by the law for the General Meeting of Shareholders. There is a clear division of responsibilities between the Management Board and the Executive Board.

The Management Board seeks that its own decisions, the decisions of the Company's management and those of the General Meeting of Shareholders, as well as the internal regulations, be lawful and properly implemented. The Board is responsible for monitoring the company management on behalf of the shareholders.

The tasks of the Management Board are described in the Company's Articles of Association and in the relevant internal regulations, available on the company's website, under the section Corporate Governance.

During the first semester of 2020, the Management Board met in 7 sessions, with a 100% presence for each session and adopted decisions that enabled it to carry out its tasks in an effective and efficient manner.

Thus, during the monthly meetings, the Management Board analyzed in detail the financial results achieved by the company during the reporting and cumulative period since the beginning of the year, as well as the economic performance in relation to the budget and to the similar period of the previous year year.

The Board requested, depending upon the situation, detailed explanations to the executive management about the plans to increase the production efficiency, about investment plans, constituted provisions, liquidity management, operational and the overall profitability.

Following the detailed analysis of the period's results, the Board decided to approve them in order to publish and send them to the Bucharest Stock Exchange and the Financial Supervisory Authority, observing each time the Financial Communication Calendar.

The 5 members of the Management Board guarantee the efficiency of the capacity to supervise, analyze and evaluate the activity of the managers, as well as the fair treatment of the shareholders.

Advisory committees

During the first semester of the year 2020, the specialized advisory committees had the following membership:

- ***The Audit Committee:*** Mr. Lucian TIMOFTICIUC, Mr. Nicolae STOIAN and Mrs. Elena CALITOIU;
- ***The Nomination and Remuneration Committee:*** Mrs. Elena CALITOIU and Mr. Dan Octavian ALEXANDRESCU;
- ***The Trade Policies Committee:*** Mr. Lucian TIMOFTICIUC and Mr. Nicolae STOIAN.

ANTIBIOTICE S.A.
EXPLANATORY NOTES TO THE FINANCIAL STATEMENTS

For the year ended on 30 June, 2020

(all the amounts are expressed in LEI, if not mentioned otherwise)

The Advisory Committees conducted investigations, analyzes and developed recommendations for the Management Board in specific areas and submitted periodic reports on their work.

Executive management

Antibiotice is represented by the General Manager, according to the powers provided by law and by the company's Articles of Association. The Management Board represents the company in relationship with the appointed managers.

The executive management of Antibiotice is ensured by a General Manager who is also the Vice President of the Board and ten speciality directors.

2 ACCOUNTING POLICIES

2.1 Declaration of conformity

The financial statements have been prepared by the company in accordance with:

- The Accounting Law no. 82 from 1991, republished and updated;
- the provisions of the Order of the Minister of Public Finance no. 2844/2016, for the approval of the Accounting Regulations conforming to the International Financial Reporting Standards, applicable to the commercial companies whose securities are admitted to trading on a regulated market, with the subsequent modifications and clarifications.

The current individual financial reports have been prepared in accordance with the criteria for recognition, measurement and evaluation according to the International Financial Reporting Standards, Interpretations and International Accounting Standards (collectively referred to as "IFRS") issued by the International Accounting Standards Board ("IASB") as adopted by the European Union ("IFRSs adopted");

The financial statements for the financial year ended on June 30, 2020 include the statement of financial position, the statement of comprehensive income, the statement of cash flows, the statement of changes in equity and the explanatory notes.

The main accounting policies applied to the preparation of the financial statements are set out below. The policies have been applied consistently to all the years presented, unless stated otherwise.

The preparation of the financial statements in accordance with the adopted IFRS requires the use of certain crucial accounting estimates. It also asks the management to use the reasoning in the process of applying the Company's accounting policies. The areas in which decisions have been made and significant estimates have been made in the preparation of the financial statements and their effect are shown below.

2.2 Bases of assessment

The separate financial statements are prepared using the historical convention / depreciated cost except for the fixed tangible assets at revalued cost by using the fair value as deemed cost and the items presented at the fair value, i.e. financial assets and liabilities at fair value through profit and

ANTIBIOTICE S.A.
EXPLANATORY NOTES TO THE FINANCIAL STATEMENTS

For the year ended on 30 June, 2020

(all the amounts are expressed in LEI, if not mentioned otherwise)

loss account, and the financial assets available for sale, except for those for which the fair value can not be reliably determined.

These financial statements have been prepared for general purposes, for the use of persons who know the provisions of the International Financial Reporting Standards, applicable to trading companies whose securities are admitted to trading on a regulated market. Consequently, these financial statements should not be considered as the only source of information by a potential investor or by another user.

2.3 Functional and presentation currency

The company's management considers that the functional currency, as defined by IAS 21 "Effects of exchange rate variation" is the Romanian leu ("RON" or "LEU"). The separate financial statements are presented in lei, the values are rounded to the nearest leu, the currency that the Company chose as the presentation currency.

The transactions made by the company in a currency other than the functional currency are recorded at the rates in force at the date when the transactions take place. The monetary assets and liabilities in foreign currencies are converted at rates in effect at the reporting date.

The profit and loss arising from the exchange rate differences following the conclusion of these transactions and from the conversion to the exchange rate at the end of the reporting period of the monetary assets and obligations denominated in foreign currency is reflected in the statement of the comprehensive income.

The exchange rates of the main foreign currencies as reported by the NBR (National Bank of Romania) are as follows:

	30-06-20	31-12-19
EUR	4.8423	4.7793
USD	4.3233	4.2608

2.4 Critical accounting assessments and estimates

As a result of the uncertainties inherent in business activities, many items in the financial statements cannot be precisely assessed, but only estimated. The estimation involves judgements based upon the latest available reliable information.

The use of reasonable estimates is an essential part for preparing the financial statements and does not undermine their reliability.

An estimate may need review if changes occur regarding the circumstances on which the estimate was based or as a result of new information or subsequent experiences. By its nature, the review of an estimate does not relate to prior periods and is not the correction of an error in the current period. Any effect, if any, on future periods is recognized as income or expense in those future periods.

The company makes certain estimates and assumptions about the future. The estimates and judgments are continually evaluated based upon the historical experience and other factors, including forecasting future events that are believed to be reasonable under the existing circumstances. In the future, the concrete experience may differ from these estimates and assumptions.

The following are examples of assessments, estimations, assumptions applied within our Company:

ANTIBIOTICE S.A.
EXPLANATORY NOTES TO THE FINANCIAL STATEMENTS

For the year ended on 30 June, 2020

(all the amounts are expressed in LEI, if not mentioned otherwise)

(a) *The evaluation of investments in land and buildings owned*

The company obtains evaluations conducted by external evaluators to determine the fair value of its real-estate investments and its buildings owned. The current assessments are based upon assumptions which include future rental income, anticipated maintenance costs, future development costs and the appropriate discount rate. Evaluators also refer to market information related to the prices of transactions with similar properties.

(b) *Adjustments for the impairment of receivables*

The assessment for the impairment of receivables is performed individually and is based upon the management's best estimate of the present value of cash flows that are expected to be received. To estimate these flows, the management makes certain estimates on the financial situation of the partners. Each impaired asset is analyzed individually. The precision in adjustments depends upon the estimates of future cash flows.

(c) *Legal proceedings*

The company reviews the unsettled legal cases following the evolutions in the legal proceedings and the existing situation at each reporting date, in order to assess the provisions and disclosures in its financial statements. Among the factors considered in decisions related to the provisions we mention the nature of litigation or claims and the potential level of damage in the jurisdiction which settles the dispute, the progress of the case (including the progress after the date of financial statements but before those statements are issued), the opinions of legal advisors, the experience in similar cases and any decision taken by the company's management related to how it will respond to the litigation, complaint, or assessment.

(d) *Cost accounting estimates*

There are objective situations in which, until the closing of some fiscal periods or up to the closing date of a financial year, the exact values of certain expenses incurred by the company are not known (e.g. marketing and promotion/sales campaigns of products, campaigns for boosting the sales). For this category of expenditure, preliminary spending will be made, which will be corrected in the following periods when cash outflows will occur. For this category of expenditure, preliminary expenses will be made, which will be corrected in future periods when an output of cash flows will occur. The estimates of expenditure for each category of expense will be made by someone with experience in the type of activity that generated the expense.

(e) *Taxation*

The taxation system in Romania is in a phase of consolidation and harmonization with the European legislation. However, there are still different interpretations of the tax legislation. In some cases, the tax authorities may have different approaches to certain issues, calculating additional taxes and penalties for their late payment. In Romania, the fiscal year has been remaining open for tax verification for a 5/7-year period. The company's management believes that the tax liabilities included in the financial statements are appropriate.

2.5 Presentation of separate financial statements

The financial statements are presented in accordance with the requirements of IAS 1 "Presentation of the financial statements". The company adopted a liquidity-based presentation in its financial position statement and a presentation of its revenue and expense according to their nature in the overall result statement, considering that these disclosures provide information that is more credible and relevant than what would have been presented under other methods allowed by IAS 1.

ANTIBIOTICE S.A.
EXPLANATORY NOTES TO THE FINANCIAL STATEMENTS
For the year ended on 30 June, 2020
(all the amounts are expressed in LEI, if not mentioned otherwise)

2.6 Intangible assets purchased

The inventory of the intangible assets is done in accordance with IAS 38 “Intangible assets” and IAS 36 “The impairment of assets”. The externally acquired intangible assets are initially recognized at cost and subsequently amortized on a straight-line basis over their useful economic life. The expenses related to the acquisition of patents, copyrights, licenses, trademarks or factory brands and other intangible assets recognized from an accounting viewpoint, with the exception of formation expenses, goodwill, intangible assets with indefinite useful life, fitted according to the accounting regulations shall be recovered by means of linear depreciation deductions for the duration of the contract or for the period of use, as the case may be.

Intangible assets generated by the company internally (development costs)

The research expenditure (or related to the research stage of an internal project) is recognized as an expense for the year to which it relates. The development costs related to projects for new products are recognized as intangible assets. They consist of: the consumption of raw materials and consumables, costs related to the hours worked for each project, other authorization fees charged by NAMMDR.

2.7. Tangible assets

The tangible assets are tangible items that:

- a) are held for use in the production of goods or the provision of services, for rental to other parties or for administrative purposes; and
- b) are expected to be used over several financial years.

Recognition:

The cost of a tangible asset item should be recognized as an asset if and only if:

- a) the entity is likely to generate future economic benefits related to the asset; and
- b) the cost of the asset can be reliably measured.

The evaluation after recognition

After the recognition as an asset, an item of property, plant and equipment is accounted for at its cost or minus the accumulated depreciation and accumulated impairment losses. After the recognition as an asset, an item of tangible assets whose fair value can be reliably measured is accounted for at a revalued amount, this being its fair value at the revaluation date.

The revaluations are made regularly enough to ensure that the accounting amount does not significantly differ from what would have been determined by using the fair value at the end of the reporting period.

The fair value of land and buildings is generally determined based upon the prices in the market through an evaluation normally performed by qualified professional assessors. The fair value of the items of tangible assets is generally their value in the market determined after evaluation.

When an item of Category I tangible asset is revalued, any accumulated depreciation at the date of revaluation is eliminated from the gross carrying value of the asset and the net value is recalculated to the revalued value of the asset. If an item of tangible assets is revalued, then the entire class of property, plant and equipment to which that item belongs is revalued.

ANTIBIOTICE S.A.
EXPLANATORY NOTES TO THE FINANCIAL STATEMENTS

For the year ended on 30 June, 2020

(all the amounts are expressed in LEI, if not mentioned otherwise)

If the carrying value of an intangible asset is increased as a result of the revaluation, then the increase is recognized in other items of the comprehensive income and accrued in equity as a revaluation surplus. However, the increase should be recognized in profit or loss to the extent that it compensates for a decrease in the revaluation of the same asset previously recognized in profit or loss.

If the carrying value of an asset is diminished as a result of a revaluation, this decrease should be recognized in profit or loss. However, the decrease should be recognized in other items of the comprehensive income to the extent that the revaluation surplus shows a credit balance for that asset. The reduction recognized in other items of the comprehensive income reduces the amount accumulated in equity as a revaluation surplus.

The revaluation surplus included in equity related to an item of property, plant and equipment is transferred directly to retained earnings when the asset is derecognised. The transfers from the revaluation surplus to the retained earnings are not made through profit or loss. If any, the effects of taxes on income from the revaluation of tangible assets are recognized and presented in accordance with IAS 12 Income Tax.

Depreciation

The depreciable amount of an asset is systematically allocated over its useful life. The depreciation of an asset begins when it is available for use, i.e. when it is in the location and condition required to operate in the desired manner.

The land owned is not depreciated.

For the depreciable fixed assets, the company utilizes, in accounting terms, the straightline depreciation method. The depreciation periods are determined by an internal specialized committee according to the company's internal procedures. Below there is a brief presentation of the lifetimes of the fixed assets by major categories of goods:

Category	Lifetime
Buildings and constructions	24-40 years
Equipment and installations	7-24 years
Means of transport	4- 6 years
Computing technology	2- 15 years
Furniture and office equipment	3- 15 years

Impairment

To determine whether an item of tangible assets is impaired, an entity applies IAS 36 the Impairment of assets. At the end of each reporting period, the entity estimates if there are indications of impairment of assets. If such evidence is identified, the entity estimates the recoverable amount of the asset.

If and only if the recoverable amount of an asset is lower than its book value, the book value of the asset will be reduced to be equal to the recoverable amount. Such a reduction represents an impairment loss. An impairment loss is immediately recognized in the profit or loss of the period in question, except when the asset is reported to the revalued amount, in accordance with another standard (for example, in accordance with the revaluation model in IAS 16 Tangible assets). Any impairment loss concerning a revalued asset is considered to be a decrease generated by revaluation.

2.8 Financial assets - IFRS 9 Financial instruments (replaces IAS 39 Financial instruments: recognition and valuation)

Initial valuation of financial assets and financial liabilities

IFRS 9 replaces IAS 39, Financial Instruments - recognition and valuation. The IASB developed IFRS 9 in three stages, which deals separately with IFRS classification and evaluation of financial assets, impairment and risk coverage. Other aspects of IAS 39, such as scope, recognition and derecognition of financial assets, have survived with only a few changes to IAS 39.

The classification on IFRS 9 is determined by the characteristics of the cash flows and the business model within which an asset is held.

Subsequent assessment of financial assets

IFRS 9 has a single model with fewer exceptions than IAS 39 which had a complex pattern. The new standard is based on the concept that financial assets should be classified and evaluated at fair value, with changes in the fair value recognized in the profit and loss account where they appear ("FVPL"), unless the restrictive criteria are met when the classification and the valuation of the asset is made at depreciated cost or at fair value through other "FVOCI" revenues).

Depreciation of financial assets

IFRS 9 eliminates the assessment of impairment for investments in equity instruments because they can now be measured only at FVPL or FVOCI without resuming changes in fair value in the profit and loss account.

Additionally, IFRS 9 establishes a new approach for loans and receivables, including commercial receivables with an "early loss" model that focuses primarily on risk.

Cash and cash equivalents / Hedging

The third major change that IFRS 9 is introducing is related to hedging; IFRS 9 allows the coverage of several exposures and the establishment of new risk coverage criteria.

2.9 Stocks

According to IAS 2, the stocks are active:

- a) held for sale in the ordinary course of business;
- b) under production for such sale; or
- c) as raw materials, materials and other consumables to be used in the production process or in the provision of services.

Stock assessment

The stocks are assessed at the lowest value between the cost and the net achievable value.

Costs of stocks

The cost of stocks includes all the purchase costs, conversion costs as well as other costs incurred in bringing the inventories to the state and location where they are now. The stocks of raw materials and consumables are stated at the cost of acquisition. The inventory outflow is performed using the Weighted Average Price method. The stocks of products in progress are stated at the value of the

ANTIBIOTICE S.A.
EXPLANATORY NOTES TO THE FINANCIAL STATEMENTS

For the year ended on 30 June, 2020

(all the amounts are expressed in LEI, if not mentioned otherwise)

raw materials and consumables included in them. The stock of finished products is recorded at production cost upon the completion of the manufacture.

Adjustments for depreciation of stocks

The stock depreciation assessment is performed individually and is based upon the best estimate of the management on the current value of the cash flows that are expected to be received. Each depreciated asset is individually analyzed. The accuracy of the adjustments depends upon the estimation of future cash flows.

The stock adjustments are based on the end-of-year calculation for adjusting the specific value of stocks of raw materials, consumables and finished products and finished products which no longer correspond from a quality viewpoint. The calculation of the general adjustment for the depreciation of inventories is based upon the validity period of existing items in stock.

2.10 Receivables

Receivables arise mainly from the provision of goods and services to customers (e.g. trade receivables), but also incorporate other types of contractual monetary assets.

The receivables are presented in the balance sheet at historical value less the adjustments for impairment in cases where it was found that the realizable value is lower than the historical value.

The impairment adjustments are recognized when there is objective evidence (such as significant financial difficulty of the partners or the non-fulfillment of payment obligations or significant payment delay) that the company will not be able to collect all the amounts due under the terms regarding the receivables and the amount of that adjustment is the difference between the net book value and the current value of expected future cash flows associated with the impaired receivable.

The assessment for the impairment of receivables is performed on an individual basis and is based upon a risk analysis based on customer categories, being the best estimate of the management regarding the current value of the cash flows expected to be received.

The Company assesses at each balance sheet date the extent to which there is any objective evidence that a financial asset (receivable) is impaired. If there is any evidence of this kind, the Company treats it differently to determine the amount of any impairment loss, depending upon the type of asset: financial assets accounted for at amortized cost, financial assets accounted for at cost and available-for-sale financial assets.

The carrying amount of the asset should be reduced either directly or by using a depreciation adjustment account. The amount of the loss should be recognized in profit or loss.

If, in a subsequent period, the value of the related impairment loss decreases and the decrease can be objectively correlated with an event occurring after the impairment has been recognized (such as an improvement in the debtor's credit rating), the loss from the previously recognized impairment should be resumed either directly or by adjusting a provision account for impairment. The resumption should not result in a carrying amount of the financial asset higher than the amount that would have been the amortized cost if the impairment would have been recognized at the date when the impairment is resumed. The value of the resumption must be recognized in profit or loss.

The adjustments for the impairment of trade receivables consist of the specific provision, entirely constituted for litigation, based upon which the general provision is calculated.

The general provision for the impairment of client receivables is calculated based upon the maturity of the outstanding receivables in the balance. The calculated depreciation adjustments may not exceed from a value viewpoint the amounts that are required to settle the trade receivable. When analyzing receivables to be cashed, based upon commercial effects, in situations where events are identified that indicate the occurrence of payment incidents or the deterioration of the debtor's

ANTIBIOTICE S.A.
EXPLANATORY NOTES TO THE FINANCIAL STATEMENTS

For the year ended on 30 June, 2020

(all the amounts are expressed in LEI, if not mentioned otherwise)

financial situation, adjustments may be calculated and the amount of the provision for impairment is at most equal to the value of the effect.

2.11 Value added tax

The Value Added Tax must be paid to the tax authorities upon the basis of the monthly VAT return until the 25th of the following month, regardless of the level of receivables recovery from customers. The tax authorities allow the VAT to be settled on a net basis. If the deductible VAT is higher than the VAT collected, the difference is refundable at the request of the company. That particular VAT may be reimbursed after a tax audit, or even in the absence thereof, if certain conditions are met. The VAT on sales and purchases that were not settled at the end of the reporting period is recognized in the statement of the financial position at net cost and presented separately as a current asset or liability. In cases where adjustments for impairment of receivables have been recorded, the impairment loss is recorded for the debtor's gross value, including VAT. The related VAT must be paid to the state budget and can be recovered only in case of the debtor's prescription as a result of the bankruptcy decision.

2.12 Financial liabilities

The financial liabilities include primarily trade payables and other short-term financial liabilities (payables related to staff, tax and duty liabilities, short-term bank debt, debt in relation to various creditors) that are initially recognized at fair value and subsequently recorded at amortized cost using the effective interest method.

2.13 Recognition of income and expenses

2.13.1 Recognition of revenues IFRS 15 - Revenues from customer contracts (replaces IAS 18 Revenues)

The income represents the gross inflow of economic benefits during the period, generated in the course of the normal activities of an entity, when these inputs result in increases in equity, other than increases related to participants' contributions to equity.

The income constitutes increases in economic benefits recorded during the accounting period, in the form of inflows or increases in assets or debt reductions, which result in increases in equity, other than those resulting from shareholder contributions.

The fair value is the value at which an asset can be traded or a debt settled between interested and knowledgeable parties, in a transaction conducted under objective conditions.

Starting with January 1, 2018, the IFRS 15 standard regarding the contracts concluded with the clients has entered into force. In some cases, IFRS 15 may require changes to current systems and this may affect some aspects related to operations.

IFRS 15 is a complex standard that introduces far more prescriptive requirements than previously included in IAS 18 Revenues, IAS 11 Construction Contracts and can therefore lead to changes in revenue recognition policies.

ANTIBIOTICE S.A.
EXPLANATORY NOTES TO THE FINANCIAL STATEMENTS

For the year ended on 30 June, 2020

(all the amounts are expressed in LEI, if not mentioned otherwise)

Income assessment

According to IAS 18, revenues were measured at the fair value of the counterperformance received or to be received, after deducting rebates or discounts. The revenues from the sale of the goods were recognized when all the following conditions were met:

- (a) the entity transferred to the buyer the significant risks and benefits related to the ownership of the goods;
- (b) the entity no longer manages the goods sold at the level at which it would normally have done in the case of their ownership and no longer has the effective control over them;
- (c) the value of the revenues can be reliably evaluated;
- (d) the economic benefits associated with the transaction are likely to be generated for the entity;
- (e) the costs incurred or to be incurred in relation to the respective transaction can be reliably evaluated.

Instead, the new standard focuses upon identifying obligations and makes a clear distinction between obligations that are satisfied "at one point in time" and those that are satisfied "over a period of time"; this is determined by the manner according to which the control of goods or services is transferred to the client. The new income model according to IFRS 15 means that we may have income recognized over a period for some results that have been accounted for as assets in accordance with IAS 18.

IFRS 15 establishes a general framework that will be applied for the recognition of revenues from a contract concluded with a client (with limited exceptions), regardless of the type of transaction or industry; The standard sets out five steps for revenue recognition:

- the identification of the contract (s) with a client;
- the identification of the execution clauses from a contract;
- the determination of the transaction price;
- the allocation of the transaction price for the execution obligations;
- the revenue recognition when (or as) the entity fulfills an obligation of execution.

Revenue is measured at the fair value of the amounts received or receivable net of VAT. Revenues are reduced by the value of returns, commercial discounts and other similar costs.

The revenues from the sale of the goods are recognized when there is an obligation to register a contract or when all the following conditions have been fulfilled:

- (a) the parties to the contract have approved the contract (in writing, verbally or according to other common business practices) and undertake to fulfill their obligations;
- (b) the company may identify the rights of each party with regard to the goods or services to be transferred;
- (c) the company can identify the payment terms for the goods or services to be transferred;
- (d) the contract has commercial content; and
- (e) it is likely that the company will collect the counterperformance to which it will be entitled in exchange for the goods or services that will be transferred to the client.

The income from the sale of the goods is recognized when the company has transferred the significant risks and benefits related to the property right to the buyer and it is likely that the company will receive those previously agreed upon after the payment. The transfer of the risks and benefits related to the property right is considered to have been accomplished once with the transfer of the legal title of ownership or with the passing of the goods in the possession of the buyer. If the

ANTIBIOTICE S.A.
EXPLANATORY NOTES TO THE FINANCIAL STATEMENTS

For the year ended on 30 June, 2020

(all the amounts are expressed in LEI, if not mentioned otherwise)

entity keeps significant risks related to the property, the transaction is not a sale and the income is not recognized.

The Company considers that the collection terms do not generate a financial component of the revenues invoiced to distributors.

Special cases: If it is found that the incomes associated with a period of the current year are free of fundamental errors, they will be corrected, during the period when the error is discovered. If the error is discovered in the following years, the correction thereof will no longer affect the income accounts, but the returned earnings account carried over from the corrections of fundamental errors, if the value of the error will be considered significant.

2.13.2 Recognition of expenses

The expenses are decreases in the economic benefits recorded during the accounting period as outflows or decreases in the value of assets or increases in debt, which are materialized through reductions in equity, other than those arising from their distribution to shareholders.

2.14 Impairment of non-financial assets (excluding the stocks, real estate investments and deferred tax assets) – IAS 36 “Impairment of assets”

The assets owned by the company, as stated in IAS 36 “Impairment of assets”, are subject to the impairment tests whenever events or changes in circumstances indicate that their accounting value may not be fully recovered. When the accounting value of an asset exceeds the recoverable amount (i.e. the highest amount between the value of use and fair value minus the selling costs) the assets is adjusted accordingly.

When it is not possible to estimate the recoverable amount of an individual asset, the impairment test is performed on the smallest group of assets to which it belongs for which there are separately identifiable cash flows; its cash-generating units (“CGUs”). The impairment costs are included in the profit and loss account unless they reduce the earnings previously recognized in other items of the comprehensive income.

2.15 Provisions – IAS 37 “Provisions, contingent liabilities and contingent assets”

The provision is measured at the best estimate of the expenses required for the settlement of the liability at the reporting date, updated at a pre-tax rate reflecting the current market assessments of the value of money over time and debt specific risks.

According to IAS 37 “Provisions, contingent liabilities and contingent assets”, a provision must be recognized, if:

- a) the Company has a current (legal or implicit) obligation generated by a past event;
- b) it is likely that an outflow of resources incorporating economic benefits will be required to settle the obligation
- c) a reliable estimate of the amount of the obligation can be made.

If these conditions are not met, a provision must not be recognized. The provisions are recorded in accountancy using the accounts from the group 15 “Provisions” and are based upon the expenses, except those related to the decommissioning of tangible assets and other similar actions related thereto, for which the provisions of IFRIC 1 will be taken into account.

ANTIBIOTICE S.A.
EXPLANATORY NOTES TO THE FINANCIAL STATEMENTS

For the year ended on 30 June, 2020

(all the amounts are expressed in LEI, if not mentioned otherwise)

The recognition, assessment and updating of provisions are made in compliance with IAS 37 "Provisions, contingent liabilities and contingent assets".

The provisions are grouped in accountancy by categories and are considered for:

- a) litigation;
- b) guarantees to customers;
- c) decommissioning of tangible assets and other similar actions related thereto;
- d) restructuring;
- e) employee benefits;
- f) other provisions.

The previously established provisions are periodically analyzed and regulated.

2.16 Benefits of employees – IAS 19 Benefits of employees

Current benefits granted to employees

The short-term benefits granted to employees include allowances, salaries, and social security contributions. These benefits are recognized as expenses when providing services.

Benefits after the termination of the employment contract

Both the Company and its employees have a legal obligation to contribute to the social security established with the National Pension Fund administered by the National House of Pensions (contribution plan founded on the principle of "pay on the way").

Therefore, the Company has no other legal or implicit obligation to pay further contributions. Its only obligation is to pay the contributions when they are due. If the Company ceases to employ people who are contributors to the financing plan of the National House of Pensions, the Company will have no obligation to pay for the benefits earned by its own employees in previous years. The Company's contributions to the contributions plan are reported as expense in the year to which they relate.

2.17 Deferred tax - IAS 12

In the deferred tax calculation, the Company will take into account the provisions of IAS 12. The deferred tax assets and liabilities are recognized when the book value of an asset or liability in the statement of the financial position differs from the tax base.

The recognition of the deferred income tax assets is limited to those moments in which the taxable profit of the next period is likely to be available.

The amount of the asset or liability is determined by using tax rates that have been enacted or adopted largely up to the reporting date and are expected to be applied when the liabilities/(assets) concerning the deferred tax are settled/(recovered).

The Company compensates for receivables and liabilities concerning the deferred tax if and only if:

- a) it has the legal right to offset the current tax receivables with the current tax liabilities; and
- b) the deferred tax receivables and liabilities relate to the income taxes charged by the same fiscal authority.

ANTIBIOTICE S.A.
EXPLANATORY NOTES TO THE FINANCIAL STATEMENTS
For the year ended on 30 June, 2020
(all the amounts are expressed in LEI, if not mentioned otherwise)

2.18 Dividends

The share of profits that is to be paid according to the law, to each shareholder is a dividend. The dividends distributed to shareholders, proposed or declared after the reporting period, as well as the other similar distributions made from the profit determined under the IFRS and included in the annual financial statements are not recognized as a liability at the end of the reporting period.

When accounting for the dividends, the provisions of IAS 10 are taken into consideration.

2.19 Capital and reserves

The capital and reserves (equity) represents the right of shareholders over the assets of an entity after deducting all liabilities. The equity includes: capital shares, reserves, reported result and the result of the financial year.

The entity was established under Law no. 31/1990 on trading companies.

In the first set of financial statements prepared under IFRS, the Company applied IAS 29 – “Financial reporting in hyperinflationary economies” for the contributions of shareholders obtained before January 1, 2004, i.e. they were properly adjusted with the inflation index.

2.20 Financing costs

An entity shall capitalize the borrowing costs that are directly attributable to the acquisition, construction or production of an asset with a long production cycle as part of the cost of that asset. An entity must recognize other borrowing costs as expenses during the period during which it bears them.

The Company did not finance the construction of long-term assets from loans.

2.21 Earnings per share

The Company shows the basic earnings per share for the ordinary shares. The basic earnings per share is calculated by dividing the profit or loss attributable to ordinary shareholders of the Company to the weighted average number of ordinary shares over the reporting period.

2.22 Reporting on segments

A segment is a distinct component of the Company that provides certain products or services (business segment) or provides products and services in a particular geographical environment (geographical segment) and which is subject to risks and benefits that are different from those of the other segments. In terms of business segments, the Company does not identify separate components in terms of associated risks and benefits.

2.23 Affiliated parties

A person or a close family member of that person is considered to be affiliated with the Company if that person:

- (i) has the control or a joint control over the Company;
- (ii) has a significant influence over the Company; or
- (iii) is a member of key management staff.

ANTIBIOTICE S.A.
EXPLANATORY NOTES TO THE FINANCIAL STATEMENTS

For the year ended on 30 June, 2020

(all the amounts are expressed in LEI, if not mentioned otherwise)

The key management staff includes those persons having authority and responsibility for planning, managing and controlling the activities of the Company, directly or indirectly, including any director (executive or non-executive) of that entity. The transactions with the key personnel include exclusively the salary benefits granted to them as shown in Note 7. "Staff Expenses".

An entity is affiliated with the Company if it meets any of the following conditions:

- (i) The entity and the Company are members of the same group (which means that each parent company, subsidiary and subsidiary of the same group is linked to the other);
- (ii) An entity is the associate or joint venture of the other entity (or associate or joint venture of a member of the group the other entity belongs to);
- (iii) Both entities are joint ventures of the same third party.
- (iv) One entity is a joint venture of a third party, and the other is an associate of the third-party entity.
- (v) The entity is a post-employment benefit plan in the benefit of the employees of the reporting entity or an entity affiliated to the reporting entity. In the event the reporting entity is itself such a plan, the sponsoring employers are also affiliates of the reporting entity.
- (vi) The entity is controlled or jointly controlled by an affiliated person.
- (vii) An affiliated person having control significantly influences the entity or is a member of the key management staff of the entity (or the parent company of the entity). The Company does not carry out transactions with entities described in points (i) – (vii) above.

3 FINANCIAL INSTRUMENTS AND RISK MANAGEMENT

The Company is exposed through its operations to the following financial risks:

- The credit risk;
- The foreign exchange risk;
- The liquidity risk.

Like all the other activities, the Company is exposed to risks arising from the use of financial instruments. This note describes the company's objectives, policies and processes for managing these risks and methods used to assess them. The additional quantitative information on these risks is presented in these financial statements. There were no major changes in the Company's exposure to financial instruments related risks in its objectives, policies and processes for managing these risks or in the methods used to assess them in comparison to the prior periods, except where otherwise stated in this note.

Main financial instruments

The main financial instruments used by the Company, of which the risk concerning the financial instruments may occur are as follows:

- Trade and other receivables
- Cash and cash equivalents;
- Investments in quoted participation titles;
- Trade and other liabilities.

A summary of the financial instruments held by category is provided below:

ANTIBIOTICE S.A.
EXPLANATORY NOTES TO THE FINANCIAL STATEMENTS
For the year ended on 30 June, 2020
(all the amounts are expressed in LEI, if not mentioned otherwise)

	Loans and receivables	
ASSETS	30-06-20	31-12-19
Trade and similar receivables	272,878,955	338,159,774
Cash and cash equivalents	3,861,622	1,877,409
Total	276,740,577	340,037,183
	Amortized cost	
LIABILITIES	30-06-20	31-12-19
Trade and similar receivables	79,450,266	72,337,840
Short-term loans	109,986,199	125,875,879
Long-term loans	68,406,475	57,080,354
Total	257,842,940	255,294,073

The overall objective of the Management Board is to establish policies that seek to reduce the risk as much as possible without affecting the competitiveness and flexibility of the Company. Further details on these policies are set out below:

Credit risk

The credit risk is the risk of financial loss for the Company, which occurs if a customer or counterparty to a financial instrument fails to meet its contractual obligations. The Company is primarily exposed to the credit risk arising from sales to customers.

Antibiotice SA has developed a Commercial Policy approved by its Management Board. This policy clearly states the commercial conditions for sale and there are conditions imposed in the selection of the clients.

Antibiotice SA cooperates solely with large distributors in the national pharmaceutical market. In all situations where possible, the export sales are paid in advance.

Calculation and analysis of the net statement (equity)

Indicators (LEI)	30-06-20	31-12-19
Short-term credits and loans	109,986,199	125,875,879
Long-term credits and loans	68,406,475	57,080,354
Cash and cash equivalents	(3,861,622)	(1,877,409)
Net debt	174,531,052	181,078,824
Total equity	495,928,763	496,842,915
Net debt in equity (%)	35.19%	36.45%

Foreign exchange risk

The Company is mainly exposed to the currency risk in the purchases made from the suppliers of raw materials, packaging and other materials outside Romania. The suppliers from whom the

ANTIBIOTICE S.A.
EXPLANATORY NOTES TO THE FINANCIAL STATEMENTS

For the year ended on 30 June, 2020

(all the amounts are expressed in LEI, if not mentioned otherwise)

company purchases these items for the production of medicines must have documents attesting the quality of their goods, as required by the European medicine registration rules. The Company cannot limit the acquisitions in third countries so much. The Financial Unit is responsible for tracking the payment deadlines and for ensuring the available funds for payment, so that the effect of foreign exchange risk to be minimized.

On June 30, 2020 the company's net exposure by types of currency to the foreign currency risk was as follows:

Assets/liabilities in EURO equivalent in LEI	For the year ended on	
	30-06-20	31-12-19
Monetary financial assets	9,625,656	8,707,724
Monetary financial liabilities	(17,251,020)	(18,661,953)
Net financial assets	<u>(7,625,364)</u>	<u>(9,954,228))</u>
RON/EUR variation	Gain/ Loss	
Appreciation of the RON against EUR by 5%	(381,268)	(497,711)
Depreciation of the RON against EUR by 5%	381,268	497,711
Impact upon result	<u>-</u>	<u>-</u>
Assets and liabilities in EUR	30-06-20	31-12-19
Monetary financial assets	1,987,827	1,821,966
Monetary financial liabilities	(3,562,567)	(3,904,746)
Net financial assets	<u>(1,574,740)</u>	<u>(2,082,780)</u>
Assets/liabilities in USD equivalent in LEI	30-06-20	31-12-19
Monetary financial assets	26,928,839	28,245,314
Monetary financial liabilities	(15,631,036)	(7,200,008)
Net financial assets	<u>11,297,803</u>	<u>21,045,307</u>
RON/USD variation		
Appreciation of the RON against USD by 5%	564,890	1,052,265
Depreciation of the RON against USD by 5%	(564,890)	(1,052,265)
Impact upon result	<u>-</u>	<u>-</u>
Assets and liabilities in USD	30-06-20	31-12-19
Monetary financial assets	6,228,769	6,629,111
Monetary financial liabilities	(3,615,533)	(1,689,825)
Net financial assets	<u>2,613,236</u>	<u>4,939,285</u>

ANTIBIOTICE S.A.
EXPLANATORY NOTES TO THE FINANCIAL STATEMENTS

For the year ended on 30 June, 2020
(all the amounts are expressed in LEI, if not mentioned otherwise)

The company's net exposure to the foreign exchange risk, equivalent in LEI, is shown in the table below:

Assets / Liabilities	30-06-20	31-12-19
LEI	92,157,352	132,333,068
EUR	(7,625,364)	(9,954,228)
USD	11,297,803	21,045,307
Other currency (CAD,GBP)	(2,106)	(1,178)
Net exposure	95,827,685	143,422,968

Given the relatively low exposure to exchange rate fluctuations, reasonable fluctuations in exchange rates are not expected to have significant effects in the future financial statements.

Liquidity risk

The liquidity risk arises from the company's management of the current assets, financing costs and reimbursement of the principal amount for its debit instruments.

The Company's policy is to provide the necessary cash for the payment of obligations when they become due. To achieve this objective, the Company seeks to maintain cash balances (or facilities agreed upon) to satisfy the payment needs.

The Management Board regularly receives cash flow forecasts as well as information on the company's available cash. At the end of the financial year, the Company has sufficient cash resources to meet its obligations in all reasonably foreseeable circumstances.

The following tables show the contractual maturities (representing outdated contractual cash flows) of the financial liabilities:

	Up to 3 months	Between 3 and 12 months	Over 12 months	Total
June 30, 2020				
Commercial and similar debt	29,399,568	50,050,698	-	79,450,266
Debts from taxes and current taxes	5,690,516			5,690,516
Short-term loans		109,986,199		109,986,199
Long-term loans			68,406,475	68,406,475
Total	35,090,084	160,036,897	68,406,475	263,533,456

	Up to 3 months	Between 3 and 12 months	Over 12 months	Total
December 31, 2019				
Commercial and similar debt	13,570,219	58,767,621		72,337,840
Debts from taxes and current taxes	13,267,396			13,267,396
Short-term loans		125,875,879		125,875,879
Long-term loans			57,080,354	57,080,354
Total	26,837,615	184,643,500	57,080,354	268,561,469

ANTIBIOTICE S.A.
EXPLANATORY NOTES TO THE FINANCIAL STATEMENTS

For the year ended on 30 June, 2020
(all the amounts are expressed in LEI, if not mentioned otherwise)

Bank liquidity

The banks where the company has bank accounts are periodically reviewed by the company's management.

Operational risk

The operational risk is the risk of some direct or indirect losses arising from a wide range of reasons associated to processes, staff, technology and infrastructure of the Company as well as from external factors, others than the credit, market and liquidity risk, such as those arising from legal and regulatory requirements and from the generally accepted standards on the organizational behavior. The operational risks arise from all the Company's operations.

The company's management is responsible for conducting operational risk related-controls. The management is supported in its mission through the development of the company's general operational risk standards in the following fields:

- The requirements for the separation of responsibilities, including the independent transaction authorization;
- The requirements for reconciling and monitoring the transactions;
- The compliance with regulatory and legal requirements;
- Documenting controls and procedures;
- Requirements for the periodic review of the operational risk the Company is exposed to and the adequacy of controls and procedures to prevent the identified risks;
- Requirements for reporting the operational losses and proposals to remedy the causes that generated them;
- The development of business continuity plans;
- Professional development and training;
- Establishing ethical standards;
- Preventing the litigation risk, including insurance, where applicable;
- The mitigation of risks, including the efficient use of insurance, where applicable.

Adequacy of capital

The management's policy regarding the capital adequacy is focused upon maintaining a sound capital base, in order to support the company's ongoing development and reach its the investment objectives.

4. SALES INCOME

The sales income includes the following items:

Description	30-06-20	30-06-19
Finished product sales	158,438,010	181,027,124
Sales of goods	27,467,695	36,378,179
Trade discounts	(39,527,775)	(45,014,208)
Total	<u>146,377,930</u>	<u>172,391,095</u>

The sales revenues are mainly driven by the sales of finished products directly to pharmaceutical distributors. The intra and extra-community sales amounted to 73.802.755 lei compared to 72.215.134 lei on 30.06.2019.

ANTIBIOTICE S.A.
EXPLANATORY NOTES TO THE FINANCIAL STATEMENTS

For the year ended on 30 June, 2020
(all the amounts are expressed in LEI, if not mentioned otherwise)

The company earns from sales in individual values higher than 10% of the total sales with a total of 5 clients.

5 OTHER OPERATING INCOME

Other operating income includes the following:

Description	30-06-20	30-06-19
Rental income	176,574	57,223
Income from research and studies	0	331,006
Income from various activities	215,084	174,599
Income from indemnities, fines and penalties	0	146,199
Other operating income	2,299,174	1,281,916
Income from adjustments for depreciation of current assets	13,615,284	11,949,570
Income from provisions for risks and expenses	3,462,643	2,098,241
Exchange rate differences	2,474,961	2,647,813
Total	22,243,720	18,686,567

6 RAW MATERIALS, CONSUMABLES AND GOODS

The expenditure on raw materials and consumables consists of:

Description	For the year ended on	
	30-06-20	30-06-19
Raw materials	40,691,253	47,360,753
Auxiliary materials	5,372,862	3,664,224
Goods	17,746,135	24,302,004
Expenditure on fuel and spare parts	1,835,857	2,132,078
Inventory items	473,329	320,029
Other consumables	279,495	239,275
Total	66,398,931	78,018,365

STAFF COSTS

The staff costs are as follows:

Description	30-06-20	30-06-19
Wages	44,941,574	42,740,485
Civil contracts	1,318,591	943,037
Tax and social contributions	1,490,763	1,404,900
Other benefits	2,395,204	1,800,051
Total	50,146,132	46,888,473

The company is managed in a unitary system within the meaning of Law 31/1990 on commercial companies; the management of the company is provided by the Management Board of SC Antibiotice SA. The Component of the Management Board and Executive Management are presented in Note 1. General Information.

The remuneration granted to the Management Board and the Executive Management is presented in the following table:

ANTIBIOTICE S.A.
EXPLANATORY NOTES TO THE FINANCIAL STATEMENTS

For the year ended on 30 June, 2020
(all the amounts are expressed in LEI, if not mentioned otherwise)

Description	30-06-20	30-06-19
Wages	3,247,072	3,129,753
Civil constructs	1,318,591	943,037
Taxes and social contributions	102,727	94,040
Total	4,668,390	4,166,830

7. OTHER OPERATING EXPENDITURE

Other operating expenditure include the following:

Description	30-06-20	30-06-19
Utilities	6,864,499	6,334,317
Repairs	279,407	699,582
Rent	233,944	176,124
Insurances	818,936	733,046
Bank fees	811,795	664,817
Advertising & promotion of products	2,169,141	3,545,629
Travel & transport	1,325,834	1,601,098
Post & telecommunications	215,299	231,225
Other services provided by third parties	4,898,389	6,646,233
Other taxes	20,153,643	22,062,544
Environment protection	563,501	531,722
Losses and adjustments of uncertain receivables	6,137,279	10,005,395
Exchange rate differences	3,888,084	3,767,421
Sundries	411,476	509,099
Total	48,771,227	57,508,252

8. FINANCIAL INCOME AND EXPENSES

The net financial income consists of:

Description	For the year ended on	
	30-06-20	30-06-19
Interest income	1,143	5,030
Interest charges	(2,739,206)	(2,192,289)
Other financial expenses	(350,915)	(72,609)
Other financial income	71,421	38,879
Total	(3,017,557)	(2,220,989)

Other financial expenses are settlement discounts on the receivables settled before maturity, materialized in bonuses granted to the company's clients for the anticipated payment of the amounts owed by them.

9. CURRENT AND DEFERRED PROFIT TAX EXPENSES AND OTHER TAXES

Description	30-06-20	30-06-19
Current tax	0	2,344,819
Deferred tax expense/(income)	206,134	231,204
Taxes specific to certain activities	0	28,508

ANTIBIOTICE S.A.
EXPLANATORY NOTES TO THE FINANCIAL STATEMENTS

For the year ended on 30 June, 2020
(all the amounts are expressed in LEI, if not mentioned otherwise)

Total	206,134	2,604,531
--------------	----------------	------------------

A reconciliation between the accounting and fiscal profit which was the basis for the calculation of corporation tax is presented in the following table:

Description	For the year ended on	
	30-06-20	30-06-19
Total income	182,094,845	205,985,573
Total expenses (without profit tax)	162,441,587	180,594,056
Gross book value	19,653,258	25,391,653
Deductions	(36,972,554)	(37,213,877)
Non-deductible expenses	24,367,065	32,691,061
Fiscal result	7,047,769	20,868,701
Profit tax (fiscal result x 16%)	1,127,643	3,338,992
Tax reductions	(1,127,643)	(994,173)
Current profit tax	0	2,344,819
Deferred profit tax	206,134	231,204
Taxes specific to certain activities	0	28,508
Total profit tax and other taxes	206,134	2,604,531

10. EARNINGS PER SHARE

Description	For the year ended on	
	30-06-20	30-06-20
Net profit (A)	19,145,254	22,319,076
Number of ordinary shares (B)	671,338,040	671,338,040
Earning per share (A/B)	0.028518	0.033246

ANTIBIOTICE S.A.
EXPLANATORY NOTES TO THE FINANCIAL STATEMENTS
For the year ended on 30 June, 2020
(all the amounts are expressed in LEI, if not mentioned otherwise)

11. TANGIBLE ASSETS

	Land	Buildings	Technical installations & equipment	Other installations, equipment & furniture	Tangible assets in progress	Total
COST						
December 31, 2018	108,306,000	108,332,084	184,961,323	7,544,355	26,453,168	435,596,930
Procurement	-	14,778,786	11,944,316	220,134	71,530,159	98,473,395
Outputs	-	10,160	3,129,954	65,985	26,943,237	30,149,336
December 31, 2019	108,306,000	123,100,710	193,775,685	7,698,504	71,040,090	503,920,989
Procurement	-	-	8,297,495	165,788	25,106,644	33,569,927
Outputs	-	317,342	4,159,949	31,019	8,463,283	12,971,593
June 30, 2020	108,306,000	122,783,368	197,913,231	7,833,273	87,683,451	524,519,323
DEPRECIATION						
December 31, 2018	-	1,726,725	117,626,773	5,306,514	-	124,660,012
Cost of the period	-	6,320,323	11,827,657	406,234	-	18,554,214
Outputs	-	10,160	3,129,954	65,984	-	3,206,098
December 31, 2019	-	8,036,888	126,324,476	5,646,763	-	140,008,126
Cost of the period	-	3,561,434	5,716,461	202,259	-	9,480,154
Outputs	-	317,342	4,159,949	31,018	-	4,508,309
June 30, 2020	-	11,280,980	127,880,988	5,818,004	-	144,979,972
PROVISION						
December 31, 2018	-	51,600	244,652	-	-	296,252
Outputs 2019	-	-	-	-	-	-
December 31, 2019	-	51,600	244,652	-	-	296,252
Outputs 2020	-	-	-	-	-	-
June 30, 2020	-	51,600	244,652	-	-	296,252
NET VALUE						
June 30, 2020	108,306,000	111,450,788	69,787,591	2,015,269	87,683,451	379,243,099
December 31, 2019	108,306,000	115,012,222	67,206,557	2,051,741	71,040,090	363,616,611
December 31, 2018	108,306,000	106,553,759	67,089,898	2,237,841	26,453,168	310,640,665

ANTIBIOTICE S.A.
EXPLANATORY NOTES TO THE FINANCIAL STATEMENTS

For the year ended on 30 June, 2020

(all the amounts are expressed in LEI, if not mentioned otherwise)

Depreciation of fixed assets

The accounting depreciation is calculated using the straight line method. For the new fixed assets, entered during the first semester of 2020, such as installations, machines and measuring and control devices, the useful life times have been established taking into account:

- the estimated level of use based on the use of the asset' capacity;
- the repair and maintenance program performed by ANTIBIOTICE SA for installations and equipment;
- the obsolescence determined by possible changes in the production process according to the structure of the product portfolio provided by the company.

The inventory value of the tangible assets constituted as pledges or guarantees is 77,567,859 lei.

12. INTANGIBLE ASSETS

The intangible assets include in-house development projects, legal documentations (for licenses and patents) as well as software licenses.

The changes in the procurement cost and amortization related to the intangible assets are presented in the table below:

	30-06-20	31-12-19
Initial balance	30,776,615	26,250,866
Inputs	4,904,440	5,836,186
Outputs	1,594,750	1,310,438
Final balance	34,086,305	30,776,615
Amortization		
Initial balance	14,390,906	11,222,150
Cost of the period	1,632,949	3,168,756
Final balance	16,023,855	14,390,906
Net value	18,062,450	16,385,709

13. STOCKS

Description	30-06-20	31-12-19
Raw materials and consumables	40,207,157	29,314,160
Production in progress	4,333,829	3,146,451
Semi-finished and finished products	55,434,478	33,849,505
Goods	14,104,725	7,665,872
Total	114,080,189	73,975,988

The value of stocks held as collateral is 34,823,504 lei.

14. TRADE AND OTHER RECEIVABLES

Description	30-06-20	31-12-19
Trade receivables	285,196,464	362,186,268
Adjustments for trade receivables	(22,380,771)	(34,066,666)
Various debtors and other receivables	4,812,907	5,069,347
Adjustments for various debtors	(3,432,707)	(3,432,707)
Receivables related to employees	15	155
Other receivables from the State Budget	4,150,202	3,159,069
Advance payments	4,532,845	5,244,308

ANTIBIOTICE S.A.
EXPLANATORY NOTES TO THE FINANCIAL STATEMENTS

For the year ended on 30 June, 2020
(all the amounts are expressed in LEI, if not mentioned otherwise)

Total	272,878,955	338,159,774
--------------	--------------------	--------------------

On June 30, 2020 the Company recorded adjustments for trade receivables representing customer balance that are unlikely to be collected by the company. The receivables of the company were analysed and evaluated according to criteria established according to the risks per categories of costumers.

Analysis of seniority	30-06-20	31-12-19
Receivables – customers	285.196.464	362.186.268
Up to 3 months	64.791.246	150.900.438
between 3 and 6 months	70.050.459	68.347.022
between 6 and 12 months	103.729.588	91.877.624
over 12 months	46.625.172	51.061.183
Value adjustments related to receivables- customers	(22.380.771)	(34.066.666)

The fluctuations in the Company's provisions for the impairment of trade receivables are presented in the following table:

Adjustments of receivables	30-06-20	31-12-19
At the beginning of the period	37,499,373	37,002,158
Established during the year	13,783,899	19,117,314
Cancelling the adjustments	(13,064,294)	(18,598,978)
At the end of the period	25,813,478	37,499,373

The value of receivables established as guaranties is 248,647,104 lei.

15. CASH AND CASH EQUIVALENTS

Description	30-06-20	31-12-19
Available in the bank	3,835,134	1,868,312
Cash and cash equivalents	26,488	9,097
Total	3,861,622	1,877,409

16. TRADE AND OTHER LIABILITIES

Description	30-06-20	31-12-19
Trade liabilities	41,991,039	39,314,006
Suppliers of assets	11,995,696	11,940,928
Employee-related liabilities	2,807,888	3,614,177
Wage provisions	4,361,035	7,149,401
Other liabilities	121,232	180,029
Interest to be paid	417,354	495,084
Taxes and social contributions	3,415,974	3,414,066
Dividends	13,429,768	5,118,284
Advance payments from customers	910,280	1,111,865
Total	79,450,266	72,337,840

ANTIBIOTICE S.A.
EXPLANATORY NOTES TO THE FINANCIAL STATEMENTS

For the year ended on 30 June, 2020
(all the amounts are expressed in LEI, if not mentioned otherwise)

17. AMOUNTS DUE TO CREDIT INSTITUTIONS

The amounts due to the credit institutions on 30.06.2020 are shown in the table below:

Amounts due to credit institutions	Value on 30.06.2020
Amounts due in the short term	109,986,198.73 LEI
Amounts due in the long term (including interest)	68,406,475.30 LEI

The short-term contract number IAS3-42-2016/17.08.2016 concluded with Unicredit Bank S.A.

Objective	Credit line – working capital
Amount	55,000,000 LEI
Maturity	16.08.2020
Balance on June 30, 2020	50,930,807.68 LEI
Warranties	Mortgage contract for buildings, land/ Receivable assignment contract

Credit contract no. IAS3-20-2018/03.05.2018 concluded with Unicredit Bank S.A.

Objective	Investment credit
Amount	15,406,300 EUR
Maturity	02.05.2028
Balance on June 30, 2020	14,126,856.10 EUR (68,406,475.30 LEI)
Warranties	Mortgage contract for buildings, land /Receivable assignment contract

The short-term contract number 12/01.07.2013 concluded with the Export-Import Bank of Romania - EXIMBANK S.A.

Objective	Credit line – working capital
Amount	30,000,000 LEI
Maturity	23.06.2021
Balance on June 30, 2020	27,312,537.01 LEI
Warranties	Mortgage contract for buildings, land /Receivable assignment contract

The short-term contract number 12239/22.05.2012 concluded with ING BANK N.V. AMSTERDAM – Romanian Branch

Objective	Credit line – working capital
Amount	9,500,000 EUR
Maturity	22.05.2021
Balance on June 30, 2020	27,550,062.97 LEI 865,867.68 EUR (4,192,791.07 LEI)
Warranties	Mortgage contract for buildings, land /Receivable assignment contract

ANTIBIOTICE S.A.
EXPLANATORY NOTES TO THE FINANCIAL STATEMENTS

For the year ended on 30 June, 2020
(all the amounts are expressed in LEI, if not mentioned otherwise)

The amounts due to credit institutions on 31.12.2019 are shown in the table below:

Amounts due to credit institutions	Value on 31.12.2019
Amounts due on short term	125,875,879 LEI
Amounts due on long term (including interest)	57,080,354 LEI

The short-term contract number IAS3-42-2016/17.08.2016 concluded with Unicredit Bank S.A.

Objective	Credit line – working capital
Amount	55,000,000 LEI
Maturity	16.08.2020
Balance on December 31, 2019	54,330,807.68 LEI
Warranties	Mortgage contract for buildings, land /Receivable assignment contract

The credit contract number IAS3-20-2018/03.05.2018 concluded with Unicredit Bank S.A.

Objective	Investment credit
Amount	15,406,300 EUR
Maturity	02.05.2028
Balance on December 31, 2019	11,943,245.63 EUR (57,080,353.84 LEI)
Warranties	Mortgage contract for buildings, land/Receivable assignment contract

The short-term contract number 12/01.07.2013 concluded with the Export-Import Bank of Romania - EXIMBANK S.A.

Objective	Credit line – working capital
Amount	30,000,000 LEI
Maturity	24.06.2020
Balance on December 2019	29,592,915.74 LEI
Warranties	Mortgage contract for buildings, land /Receivable assignment contract

The short-term contract number 12239/22.05.2012 concluded with ING BANK N.V. AMSTERDAM – Romanian Branch

Objective	Credit line – working capital
Amount	9,500,000 EUR
Maturity	22.05.2020
Balance on December 31, 2019	24,021,730.10 LEI 3,251,946.88 EUR (15,542,029.72 LEI) 560,551.01 USD (2,388,395.74 LEI)

ANTIBIOTICE S.A.
EXPLANATORY NOTES TO THE FINANCIAL STATEMENTS

For the year ended on 30 June, 2020
(all the amounts are expressed in LEI, if not mentioned otherwise)

Warranties	Mortgage contract for buildings, land /Receivable assignment contract
------------	---

SC Antibiotice SA has not lodged guarantees and has not pledged or mortgaged its own assets to guarantee obligations in favour of a third party.

18. INVESTMENTS SUBSIDIES

The subsidies for investments have the following structure:

Subsidies for investments	30-06-20	31-12-19
Wastewater treatment plant	2,140,894	2,220,345
Research project-UMF Iasi	24,503	24,503
Other grants from European funds	567,457	615,426
Other grants from state budget funds	109,748	118,213
Other amounts received in the form of grants	83,422	100,682
Total	2,926,024	3,079,169

The amounts reflected in the account subsidies for investments represent values received by the company in the form of grants during the last 10 years for investments in the environmental protection and in increasing the competitiveness of industrial products through financing from the Ministry of Economy, Trade and Business Relations and UEFISCDI Bucharest.

19. DEFERRED INCOME TAX

The variation of debts regarding the deferred income tax is presented in the following table:

Description	30-06-20	31-12-19
Initial balance	25,531,938	25,266,930
Cost/(income) deferred tax	206,134	265,008
Final balance	25,738,072	25,531,938

The main components of the deferred tax are: deferred tax related to the revaluation of fixed assets during the period 2004-2009 and the deferred tax related to re-evaluations in the years 2012 and 2015.

20. SHARE CAPITAL

The subscribed share capital of the company on June 30, 2020 is 67,133,804 lei, the nominal value of a share is 0,1000 lei/share. Our company has a number of 671,338,040 shares which confer equal rights to the company's shareholders. SC Antibiotice SA has not issued preference shares to shareholders.

ANTIBIOTICE S.A.
EXPLANATORY NOTES TO THE FINANCIAL STATEMENTS

For the year ended on 30 June, 2020
(all the amounts are expressed in LEI, if not mentioned otherwise)

According to the provisions of IAS 29 – hyperinflationary economies, the share capital was restated taking into account the inflation index communicated by the National Statistics Commission. It was applied starting with the balance determined according to GD 500/1994, from the reporting date to 31.12.2003, the date when it was considered that the national economy has ceased to be hyperinflationary.

Subsequent to 31.12.2003, the share capital increased according to the historical amounts registered with the Trade Registry.

On 31.12.2012, in the balance sheet of the Company there was a retained earnings loss result from the application for the first time of IAS 29 “*Financial Reporting in Hyperinflationary Economies*” proposed to be covered from the amount resulting from the application of IAS 29 “*Financial Reporting in Hyperinflationary Economies*” as follows:

Reported loss result from the first application of IAS 29	197,701,352
Adjustments of the share capital-the first application of the IFRS	197,701,352

According to the Order 1690/2012 regarding the modifying and filling out of some accounting regulations, the accountable loss reported, coming from the transition to IFRS, from following for the first time of IAS 29, as well as the one resulting from the use, at the date of transition to the application of IFRS, of the fair value as deemed cost is covered from equity (including the amounts reflected in the account credit 1028 “Adjustments of the share capital”), according to the GMS decision, with compliance of the legal provisions.

21. RESERVES

Reserves include the following components:

Description	30-06-20	31-12-19
Reserves from revaluation of fixed assets	58,927,412	60,481,330
Legal reserves	13,426,761	13,426,761
Deferred income tax recognized on equity	(9,428,384)	(9,677,011)
Other reserves	204,149,956	193,386,084
Reserves from current profit		7,269,283
TOTAL	267,075,745	264,886,447

The following describes the nature and purpose of each reserve within the equity:

Reserve	Description and purpose
Reserves from revaluation of fixed assets	If the book value of a tangible asset is increased as a result of the re-evaluation, then the increase should be recognized in other items of global result and cumulated in equity, as a re-evaluation surplus. The revaluation reserves cannot be distributed and cannot be used to increase the share capital.

ANTIBIOTICE S.A.
EXPLANATORY NOTES TO THE FINANCIAL STATEMENTS

For the year ended on 30 June, 2020

(all the amounts are expressed in LEI, if not mentioned otherwise)

Legal reserves	According to Law 31/1990, at least 5% of the profit is taken each year for the formation of the reserve fund until it reaches at least a fifth of the share capital.
Other reserves	Other reserves include reserves that represent tax incentives that cannot be distributed because they have implications on the recalculation of the corporate tax. The difference represents reserves made up of profits.

22. REPORTED RESULT

The reported result includes the following components:

Description	30-06-20	31-12-19
Reported result – a surplus from revaluation reserves	18,727,605	17,422,314
Result reported from error correction	-	-
The retained earnings arising from the use of fair value as deemed cost at the date of transition to IFRSs	123,846,355	123,846,355
The retained earnings from the adoption of IAS 29 for the first time	(197,701,352)	(197,701,352)
Total	<u>(55,127,392)</u>	<u>(56,432,683)</u>

23. CONTINGENT LIABILITIES

SC Antibiotice SA does not have contingent liabilities on June 30, 2020.

24. ELEMENTS FOLLOWING THE REPORTING PERIOD

There are no further significant elements that were not presented in the present financial situations.

25. INFORMATION ABOUT THE AUDIT OF FINANCIAL STATEMENTS

The financial audit on 30.06.2020 was carried out by SC SOCECC SRL. The auditor provided only financial audit services.

Accounting, Expertise & Accounting Consultancy Company
SOCECC Ltd.

INDEPENDENT AUDITOR'S REPORT
on
the INTERIM FINANCIAL STATEMENTS DRAWN UP by
ANTIBIOTICE S.A. for the FIRST SEMESTER of 2020

BUCHAREST

-2020-

INDEPENDENT AUDITOR'S REPORT
TO THE SHAREHOLDERS OF ANTIBIOTICE S.A.

Review Report of Interim Financial Statements

We reviewed the interim financial statements of **ANTIBIOTICE S.A. ("The Company")** comprising the financial position statement as of June 30, 2020, statement of comprehensive income, statement of changes in equity and cash flow statement for the 6-month period ended on June 30, 2020 as well as a summary of the significant accounting policies and other explanatory notes.


The Management is responsible for the preparation and accurate presentation of these interim financial statements in accordance with the International Financial Reporting Standards (IFRS) adopted by the European Union. It is our responsibility to express a conclusion regarding this interim financial information, based on our review.

Area of review


We conducted the review in accordance with the International Standard on Review Engagements **2410 "Review of interim financial statements, performed by an independent auditor of the entity"**. A review of interim financial information consists of interviewing especially persons responsible for financial and accounting matters, and applying analytical and other review procedures. The area of a review is substantially smaller than the area of an audit, conducted in accordance with the International Standards on Auditing and we are not allowed to obtain assurance that we would have identified any material issues that could have been identified in an audit. Therefore, we do not express an audit opinion.

Conclusion

Based on our review, we did not identify any issues that would lead us to believe that the interim financial statements prepared by ANTIBIOTICE S.A. on June 30, 2020 are not prepared in all material respects in accordance with IFRS.



illegible signature



Bucharest, July 31, 2020

In the name of,

Accounting, Expertise & Accounting Consultancy Company - SOCECC Ltd.
headquartered in Bucharest, registered in the Electronic Public Register with the no. FA227
through **Zegrea Laurențiu**, registered in the Electronic Public Register with the no. AF2666